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IDENTIFICATION AND ASSESSMENT OF LONGITUDINAL
BIOMARKERS USING FRAILTY MODELS IN SURVIVAL ANALYSIS
Feng-shou Ko, PhD
University of Pittsburgh, 2006
A biomarker is a measurement which can be used as a predictor or sometimes even a surro-
gate for a biological endpoint that directly measures a patient’s disease or survival status.
Biomarkers are often measured over time and so are referred to as longitudinal biomarkers.
Biomarkers are of public health interest because they can provide early detection of life
threatening or fatal diseases.
It is important in public health to be able to identify biomarkers to predict survival for
patients because it can reduce the time and cost necessary to resolve the study question or
used to identify subsets of patients who would be appropriate candidates for the administra-
tion of a targeted therapy. In this dissertation, we introduce a method employing a frailty
model to identify longitudinal biomarkers or surrogates for a time to event outcome. Our
method is an extension of earlier work by Wulfson, Tsiatis, and Song where it was assumed
that the event times have the same baseline hazard. In our method, we allow random effects
to be present in both the longitudinal biomarker and underlying survival function. The
random effect in the biomarker is introduced via an explicit term while the random effect in
the underlying survival function is introduced by the inclusion of frailty parameters into the
model. We use simulations to explore how the number of individuals, the number of time
points per individual and the functional form of the random effects from the longitudinal
biomarkers influence the power to detect the association of the longitudinal biomarker and
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the survival time. We also explore effect of missingness on how a biomarker predicts a time
to event outcome. We conclude that for a given sample size, the biomarker effectiveness for
relatively small numbers of subjects and large numbers of observed time points is better than
for relatively large numbers of subjects and small numbers of observed time points. We also
conclude that when the missing data mechanism is missing at random (MAR), our method
works reasonably well. However, when the missing data mechanism is non-ignorable, our
method doesn’t perform well in determining whether or not potential biomarkers are good
predictors of a time to event outcome. Finally, we apply our method to liver cirrhosis data
and conclude that prothrombin is a good predictor of time to liver cirrhosis and thus, can
be used as a potential surrogate for liver failure.
Key Words: surrogate; biomarker; multivariate survival; frailty model.
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1.0 INTRODUCTION
A biological characteristic that is a surrogate for an outcome of interest is referred to as
a biomarker. In a clinical trial, it is often useful to be able to identify a biomarker as a
surrogate for the outcome of interest because the use of the surrogate can reduce the time
and cost necessary to resolve the study question or used to identify subsets of patients who
would be appropriate candidates for the administration of a targeted therapy. Longitudinal
data analysis and survival analysis have been used broadly as individual methods to analyze
biological and medical studies. In recent years, some investigators have employed these two
statistical methodologies in a combined approach to analysis. Joint modeling methods are
the potential to exploit the longitudinal biomarker as a surrogate for the subsequent survival.
Individual-level surrogacy for a survival endpoint will be focused in this study. A score test
for association between survival time and biomarker values is developed.
Traditionally, a longitudinal biomarker is used for monitoring survival based on the
assumption that the baseline hazard for each observation is homogeneous. However, many
studies show that the assumption that the survival time for each observation is homogeneous
is not adequate. For example, the survival analysis of twins study, the occurrence of the
events such as the death is not based on the homogeneous baseline hazard. Other examples
include the study of the diabetic retinopathy and the recurrent event study, the occurrence
of the event is also not based on the homogeneous baseline hazard. Hence, it is necessary to
develop a more adequate method to deal with the studies about the longitudinal biomarker
as the surrogate, which is used for monitoring the survival situation for the patients when
the association of the observation times is dependent.
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In recent years, frailty models are used to deal with a heterogenous hazard in survival
analysis. Frailty models are basically random effects models for the survival data, where
the random effects are specified by means of the hazard function. Gamma, Weibull, and
lognormal distribution are usually assumed as the distribution of frailty models.
The efficacy of individual-level biomarkers is also considered. From one point of view, an
effective surrogate is one for which the conditional residual lifetime distribution accounting
for biomarkers information at an interim time is more strongly concentrated around the
actual, but as-yet unobserved, survival time than is the marginal residual lifetime distribution
ignoring the biomarker data. When a biomarker is considered to be a surrogate, a statistical
method is necessary to determine the effectiveness of the surrogate. An effective surrogate is
very useful for the investigator to predict the patients’ survival status. In survival analysis,
predictive accuracy for the individual patients should be distinguished from the accuracy of
survival function estimates. The appropriate method to determine an effective surrogate is
very important for the multivariate survival analysis.
In this dissertation, we will try to address the following problems:
1. How to determine a longitudinal biomarker as a surrogate for survival with heterogeneous
hazard
2. How to deal with measurement errors for the covariates in the Cox model
3. Finding a joint model for the combined analysis of survival with heterogeneous hazard
and longitudinal data
4. Effectiveness of biomarkers as surrogate endpoints
Accordingly, the specific goals of this dissertation are to:
1. Extend the method proposed by Henderson, Diggle, and Dobson (2002) for survival with
heterogeneous hazard data will be developed.
2. Develop the joint likelihood function which combines the likelihood functions of the
longitudinal biomarkers and survival with heterogeneous hazard distribution.
3. Develop a survival with heterogeneous hazard model based on a frailty model.
4. Incorporate frailty into the semi-parametric hazard model (Cox model); and
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5. Develop the methodology to determine the effectiveness of potential longitudinal biomark-
ers for survival with heterogeneous hazard data.
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2.0 REVIEW OF KEY LITERATURE
2.1 LONGITUDINAL BIOMARKER AS A SURROGATE
The idea of using one endpoint as a surrogate for a later occurring endpoint has been explored
extensively over the last 25 years. Paterson, et al. (1985) [1] discussed the association
between the response to treatment and survival of patients who have metastatic breast
cancer. In their study, the response to treatment was classified into complete response,
partial response, stable disease, and progressive disease. They found that survival time
among the patients with different responses to treatment were not significantly different
even when controlling for menopausal status and treatment method except patients who
were classified into progressive disease. Patients who were classified as having progressive
disease had a shortened survival time. They suggested that the assessment of a treatments
worth should be based as much on the patients subjective feeling of well-being as on the
magnitude of the tumor response.
Gail [2] published a paper evaluating serial cancer markers in patients at risk of recurrent
disease. He showed that high levels of carcinoembryonic antigen (CEA) are associated with
increased risk of death in patients with resected colorectal cancer. He also defined time
dependent functions, Z (t), which summarize the marker history up to time t. These functions
were tested to determine whether the marker was related to risk of death (or recurrence).
A parameter, γ, denoted the value of a marker at time t and the marker history for an
individual was defined as M = {γ(t) : 0 ≤ τ ≤ t}. He specified the following definitions of Z
(t):
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Z1 (t) = γ(t);
Z2 (t) = γ(t− ω);
Z3 (t) = 1 if sup γ(t) ≥ η, 0 ≤ τ ≤ t, 0 otherwise; and
Z4 (t) = {γ(t)− γ(t− ω)}/∆.
Z1 (t) is the simplest function and may be used to study the question, “Are those with
elevated marker values at time t at higher risk at a given time than those without elevated
marker values?” Z2 (t) may be used to test whether those with elevated marker values at
time t− ω at higher risk at time t. Z3 (t) could be used to assess if any previous elevation
of the marker increases risk, and Z4 (t) could be used to see if a high rate of increase in the
marker has grave prognostic significance. Gail commented about some generic features of
the serial marker data problem:
(1) The risk of death may be influenced by other prognostic factors which could obscure
the effect of the serial marker;
(2) There is often insufficient information to justify a particular parametric model for an
analysis;
(3) The time to death data are variably censored on the right;
(4) The marker value γ(t) is only measured at a finite number of points; and
(5) Occasionally one has no idea what value to assign γ(t) or Z (t) because no proximate
values are available.
Gail provided some methods to solve these problems. The first three problems arise
whenever one attempts a covariate analysis on survival data, and the semiparametric ap-
proach of Cox is well adapted to these problems. Other prognostic factors can be adjusted
by stratification and allow a separate nuisance hazard function for each stratum. Problem
(4) requires the data analyst to define an interpolation convention to assign values γ(t) for
t intermediate times between observations. The partial likelihood ratio method of Cox is
particularly useful for problem (5), because it allows patients to contribute to “risk sets”
when, and only when, a valid marker measurement is available. “Proximate” in (5) means
we’re interested in the neighborhood area around the interest of time point t or t - ω. That
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is, the interval of (t−∆t, t+∆t) or (t−ω−∆t, t−ω+∆t). A marker measurement, γ(t), is
said to be censored if no proximate measurements are available; otherwise, γ(t) is said to be
a valid marker measurement. Likewise, the experiment yields a valid marker measurement or
censored functional measurement according as sufficient proximate observations are or are
not available to determine Z (t). For the same set of marker measurements, some functions,
such as the slope Z4(t), may be censored and others, such as Z1(t) may be valid.
Tsiatis, DeGruttola, and Wulfsohn tried to find a good surrogate marker to evaluate new
treatments in acquired immune deficiency syndrome (AIDS) clinical trials [3]. The Cox pro-
portional hazards regression model was used to study the relationship between CD4 counts
as a time-dependent covariate and survival. The authors indicated that a good surrogate
biomarker should have the following properties: 1) it should be related to prognosis; 2) the
distribution of the values for the biomarker should be different for individuals receiving an
effective treatment versus those receiving a placebo; and 3) the beneficial effects of a good
treatment should be mediated through its effect on the marker. In other words, patients
with the same value of a biomarker should have the same prognosis whether they are receiv-
ing a treatment or a placebo. In such a case, the better prognosis associated with a good
treatment could be explained by the change in the value of the marker for that treatment.
The authors also commented that the standard methods for estimating the parameters in the
Cox model by maximizing the partial likelihood are not appropriate because the CD4 counts
are measured only periodically and with substantial measurement error because of biological
variation. They proposed a two-stage method approach to estimate the parameters. In the
first stage, the longitudinal CD4 count data are modeled using a repeated measures random
components model. In the second stage, methods for estimating the parameters in a Cox
model when the data are assumed to be of this form are derived. Tsiatis, DeGruttola, and
Wulfsohn also used the new methods to deal with the questions about the missing data.
They analyzed the CD4 data from a randomized clinical trial of AIDS patients where half
of the patients were randomized to receive Zidovudine (ZDV) and the other half of them
were randomized to receive a placebo. The results of the study showed that the CD4 counts
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might not serve as a useful surrogate biomarker for assessing treatments for the population
of patients.
Weiss, Bunce, and Hokanson commented that the comparison of survival distributions be-
tween responding and non-responding patients can be difficult in interpretation and method-
ology [4]. The statistical test only shows the association between response and survival but
it does not mean that the relationship of the cause and effect exists since the assignment of
patients into groups is not random. Because this association might have no relevance to the
efficacy of treatment, it is difficult to interpret the efficacy of treatment by the comparing
the survival distributions of responding and non-responding patients. Besides, variability
in the definition of a non-responder and the handling of early deaths could cause different
conclusions concerning survival.
Wittes, Lakatos, and Probstfield discussed surrogate endpoints for cardiovascular dis-
ease in clinical trials [5]. They defined a surrogate endpoint as an endpoint measured as
an alternative to some other ”true endpoint”. A surrogate is especially useful if it is easily
measured and highly correlated with the true endpoint. Often, the true endpoint is one with
clinical importance to the patient, for example, mortality or a major clinical outcome, while
a surrogate is one biologically closer to the process of disease, for example, cardiac ejection
fraction. Use of the surrogate can often lead to dramatic reductions in sample size and
much shorter studies than use of the true endpoint. Several problems common in trials with
surrogate endpoints are discussed in the paper. Most important is the effect of missing data,
especially in the face of informative censoring. Wittes, Lakatos, and Probstfield suggested
three possible methods for dealing with missing endpoints in clinical trial. First, analyze
the data available and ignore the fact that some observations are missing. This is the most
common approach and has large potential bias. Second, use a formal statistical method to
attempt to reduce the bias caused by informative censoring. The simplest approach is to
assign a score to the missing value. More complicated methods are under investigation, but
as mentioned above, have little practical use if a large proportion of data is missing. Third,
use an informal rule to penalize a study with missing data or as part of a sensitivity analysis.
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They also commented on the heterogeneity of variance as another problem common to many
surrogate endpoints and commented that the required sample size is often too small to detect
infrequent but major adverse effects of therapy.
A major obstacle in the study of the etiology of chronic disease and the development
of effective prevention is the long latent period between the initiation of the disease and its
diagnosis. Prospective studies relating possible risk factors to disease or investigating the
effects of an intervention on disease incidence therefore require extended periods of follow-
up. Such studies are costly. Freedman, Graubard, and Schatzkin [6] defined intermediate
endpoints (IE) that are biological markers or events that may be assessed or observed prior
to the clinical appearance of the disease, and that bear some relationship to the development
of that disease. In the study of chronic disease, the use of IE can shorten the duration of
follow-up time needed to assess the efficacy of an intervention or the association of a risk
factor with outcome. They listed four points about how intermediate points may be studied
and validated. First, intermediate endpoints should usually be validated within prospective
studies, either observational cohort studies or experimental intervention trials. Second, in a
cohort study we need to examine the exposure–IE–disease relationship; in an intervention
study the intervention–IE–disease relationship should be examined. Third, intermediate end-
points for a disease can only be validated in reference to a given exposure (or intervention).
Once validated for that exposure the IE may be considered valid for other exposures that
affect the disease through the same pathway. Fourth, the criterion for validation is that the
exposure (or intervention) effect on disease, adjusted for the intermediate endpoint, is equal
to zero. Freedman, Graubard, and Schatzkin also analyzed the data from the lipid research
clinics coronary primary prevention trial to examine whether serum cholesterol level is an
intermediate endpoint for coronary heart disease (CHD) by investigating the effect of the
cholesterol lowering drug cholestyramine on CHD incidence adjusted for serum cholesterol
levels. They found serum cholesterol level is not a good intermediate endpoint for coronary
heart disease (CHD).
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In 1992, Pepe [7] discussed inference using surrogate outcome data and a validation sam-
ple. In her study, most subjects only had covariates and surrogate response data. Few sub-
jects had complete data including true outcome response. Parametric and semi-parametric
methods were used to estimate such data.
Buyse, et al. [8] discussed validating surrogate endpoints via meta-analyses of random-
ized experiments and commented on the definition of a surrogate as presented by Prentice
[9]. Prentice had defined a surrogate endpoint as response variable for which a test of the
null hypothesis of no relationship to the treatment groups under comparison is also a valid
test of the corresponding null hypothesis based on the true endpoint. If T and S are random
variables that denote the true and surrogate endpoints, respectively, and Z is an indicator
variable for treatment, then, using the notation of Buyse et al., Prentice’s definition can be
written as follows: f (S| Z) = f (S) iff f (S| T) = f (S), where f (S) denotes the probability
distribution of the surrogate endpoint, f (S| T) denotes the probability distribution of the
surrogate endpoint conditional on the value of the true endpoint, and f (S| Z) denotes the
probability distribution of S conditional on the value of Z, an indicator variable for treat-
ment. As such, the definition is of limited value since a direct verification that a triplet
(T, S, Z) fulfills the definition would require a large number of experiments to be available
with information on the triplet. Operational criteria are therefore needed to check if Pren-
tices definition is fulfilled. Buyse et al., commented that four operational criteria have been
proposed to check if the triplet (T, S, Z) fulfills the definition. The first two criteria are:
1) f (S|Z) 6= f (S) and; 2) f (T|Z) 6= f (T). Both of these criteria are consistent with Pren-
tice’s definition. In practice, due to lack of power, the validation of these criteria requires
Z to have an effect on both T and S. It has been pointed out that requiring Z to have a
statistically significant effect on T may be excessively stringent, because in that case, from
the limited perspective of significance testing, there would no longer be a need to establish
the surrogacy of S. The two other criteria are: 3) f (T|S) 6= f (T) and 4) f (T|S, Z) = f
(T|S). It can be proven that criterion #3 is sufficient for Prentices definition in all cases,
and criterion #4 is sufficient for binary endpoints but not in general. These four operational
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criteria are informative and will tend to be fulfilled for valid surrogate endpoints, but they
should not be regarded as strict criteria. Criterion #4, f (T|S, Z) = f (T|S) captures the
essential notion of surrogacy by requiring that the treatment is irrelevant for predicting the
true outcome, given the surrogate. Buyse et al. commented that f (T|S, Z) = f (T|S) raises
a conceptual difficulty in that it requires the statistical test for treatment effect on the true
endpoint to be non-significant after adjustment for the surrogate. The non-significance of
this test does not prove that the effect of treatment upon the true endpoint is fully captured
by the surrogate. However, it is proposed to calculate the proportion of the treatment effect
explained by surrogate. A good surrogate is one for which this proportion explained (PE) is
close to unity based on this concept (f (T|S, Z) = f (T|S) would require that PE = 1). Then
they argued this concept and proposed an alternative. They used two related quantities
to replace PE. One is the relative effect (RE) that is the ratio of the effects of treatment
upon the final and the surrogate endpoint. The other is the treatment-adjusted association
between the surrogate and the true endpoint, ρz.
Buyse and Molengerghs commented criteria for the validation of surrogate endpoints in
randomized experiments [10]. They focused on the cases where the surrogate and the final
endpoints were both binary and normally distributed. Letting T and S be random variables
that denote the true and surrogate endpoint, respectively, and Z be an indicator variable for
treatment, Prentice’s criteria are fulfilled if Z has a significant effect on T and on S, if S has
a significant effect on T, and if Z has no effect on T given S. Freedman relaxed the latter
criterion by estimating PE, the proportion of the effect of Z on T that is explained by S,
and by requiring that the lower confidence limit of PE be larger than some proportion, say
0.5 or 0.75. This condition can only be verified if the treatment has a massively significant
effect on the true endpoint, a rare situation. They argued that two other quantities must
be considered in the validation of a surrogate endpoint: RE, the effect of Z on T relative to
that of Z on S, and γz, the association between S and T after adjustment for Z. A surrogate
is said to be perfect at the individual level when there is perfect association between the
surrogate and the final endpoint after adjustment for treatment. A surrogate is said to be
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perfect at the population level if RE is 1. A perfect surrogate fulfills both conditions, in
which case S and T are identical up to a deterministic transformation. Fieller’s theorem was
used for the estimation of PE, RE, and their respective confidence intervals. Logistic regres-
sion models and the global odds ratio models were used for binary endpoints. Linear models
were employed for continuous endpoints. In order to be of practical values, the validation of
surrogate endpoints was shown to require large numbers of observations.
In 2000, Gail, et al., discussed the strengths and weaknesses of the meta-analytic ap-
proach to estimate the effect of a new treatment on a true clinical outcome measure, T, from
the effect of treatment on a surrogate response, S [11]. The meta-analytic approach uses
data from a series of previous studies of interventions similar to the new treatment. The
data are used to estimate relationships between summary measures of treatment effects on
T and S that can be used to infer the magnitude of the effect of the new treatment on T
from its effects on S. The class of models is extended to cover a broad range of applications
in which the parameters define features of the marginal distribution of (T, S). A bootstrap
procedure is also presented to allow for the variability in estimating the distribution that
governs the between-study variation. Gail, et al. noted that ignoring this variability can
lead to confidence intervals that are much too narrow. They also noted that, compared to
direct measurement on T , the meta-analytic approach has limitations including the likely
serious loss of precision and difficulties in defining the class of previous studies to be used to
predict the effects on T for a new intervention.
Bruzzi commented on phase II studies that used tumor response to chemotherapy as the
primary endpoint to evaluate the anti-tumor activity of new drugs [12]. He concluded that
tumor response is indeed a valid surrogate endpoint of survival in colorectal cancer, and that
there is strong indirect evidence supporting a similar role of tumor response in breast cancer.
The author commented that this biomarker may be a good candidate for use as a surrogate
in the trial of metastatic breast cancer to aid in decision for testing patients.
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2.2 MEASUREMENT ERRORS FOR THE COVARIATES IN THE COX
MODEL
Hu, Tsiatis, Davidian commented that estimating the parameters in the Cox model when
covariate variable are measured with error [13]. The Cox proportion hazards model is com-
monly used to model survival data as a function of covariates. Because of the measuring
mechanism or the nature of the environment, covariates are often measured with error and
are not directly observable. A naive approach is to use the observed values of the covari-
ates in the Cox model, which usually produces biased estimates of the true association of
interest. An alternative strategy is to take into account the error in measurement, which
may be carried out for the Cox model in a number of ways. They examined several such
approaches and compare and contrast them through several simulation studies. They intro-
duced a likelihood-based approach, which they referred to as the semiparametric method,
and showed that this method was an appealing alternative. The methods were applied to
analyze the relationship between survival and CD4 count in patients with AIDS.
Tsiatis and Davidian [14] discussed a semiparametric estimation for the proportional
hazards model with longitudinal covariates measured with error. They commented that
a common objective in longitudinal studies is to characterise the relationship between a
failure time process and time-dependent covariates are generally available as longitudinal
data collected periodically during the course of the study. They assumed that these data
follow a linear mixed effects model with normal measurement error and that the hazard of
failure depends both on the underlying random effects describing the covariate process and
other time-independent covariates through a proportional hazards relationship. A routine
assumption is that the random effects are normally distributed; however, this need not hold
in practice. Within this framework, they developed a simple method for estimating the
proportional hazards model parameters that required no assumption on the distribution of
the random effects. Large-sample properties were discussed, and finite-sample performance
is assessed and compared to competing methods via simulation.
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Liu, Mazumdar, Stone, Dew, Houck, Reynolds [15] commented Accounting for covariate
measurement error in a Cox model analysis of recurrence of depression. When a covariate
measured with error is used as a predictor in a survival analysis using the Cox model,
the parameter estimate is usually biased. In clinical research, covariates measured without
error such as treatment procedure or sex are often used in conjunction with a covariate
measured with error. In a randomized clinical trial of two types of treatment, we account for
the measurement error in the covariate, log-transformed total rapid eye movement (REM)
activity counts, in a Cox model analysis of the time to recurrence of major depression in an
elderly population. Regression calibration and two variants of a likelihood-based approach
are used to account for measurement error. The likelihood-based approach is extended to
account for the correlation between replicate measures of the covariate. Using the replicate
date decreases the standard error of the parameter estimate for correlation between replicates
can affect results in a Cox model analysis and should be accounted for. In the depression
data, these methods render comparable results that have less bias than the results when
measurement error is ignored.
2.3 JOINT MODELS FOR SURVIVAL AND LONGITUDINAL DATA
ANALYSIS
Wulfsohn and Tsiatis discussed a joint model for survival and longitudinal data measured
with error [16]. They commented that the relationship between a longitudinal covariate
and a failure time process can be assessed using the Cox proportional hazards regression
model. They considered the problem of estimating the parameters in the Cox model when
the longitudinal covariate is measured infrequently and with measurement error. They as-
sumed a repeated measures random effects model for the covariate process. Estimates of the
parameters were obtained by maximizing the joint likelihood for the covariate process and
the failure time process. This approach used the available information optimally because
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they use both the covariate and survival data simultaneously. Parameters were estimated
using the expectation-maximization algorithm. They argued that such a method is supe-
rior to naive methods where one maximizes the partial likelihood of the Cox model using
the observed covariate values. It also improves on two-stage methods where, in the first
stage, empirical Bayes estimates of the covariate process were computed and then used as
time-dependent covariates in a second stage to find the parameters in the Cox model that
maximize the partial likelihood.
Henderson, Diggle, and Dobson discussed the joint modeling of longitudinal measure-
ments and event time data [17]. A class of models is formulated for the joint behavior of a
sequence of longitudinal measurements and an associated sequence of event times, including
single-event survival data. Special cases of the model class are discussed in detail and an es-
timation procedure which allows the two components to be linked through a latent stochastic
process is described.
Huang and Louis commented nonparametric estimation of the joint distribution of sur-
vival time and mark variables [18]. In many applications, variables of interest were marks
of the endpoint which were not observed when the survival time was censored. They fo-
cused on nonparametric estimation of the joint distribution and summaries of survival time
and mark variables. They established a representation of the joint distribution function
through the cumulative mark-specific hazard function, which was analogous to the prod-
uct integral representation of univariate survival function. They identified a basic structure
common to various applications, proposed nonparametric estimators and showed that they
examined the likelihood. They formulate the problem in the marked point process frame-
work and study both finite and large-sample properties of the estimators. We showed that
the joint distribution function estimator was nearly unbiased, uniformly strongly consistent
and asymptotically normal. They also derived asymptotic variances for the estimators and
propose sample-based variance estimates. Numerical studies demonstrated that both the es-
timators and their variance estimates performed well for practical sample sizes. They outline
an application strategy.
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Lin, Turnbull, McCulloch, and Slate commented latent class models for joint analysis of
longitudinal biomarker and event process data [19]. They commented that latent class models
that incorporated both a longitudinal biomarker process and an event process offered a way to
handle additional heterogeneity, to uncover distinct subpopulations, to incorporate correlated
nonnormally distributed outcomes, and to classify individuals into risk classes. Their latent
class joint model can aid the prediction of outcome variable probability given the longitudinal
biomarker information available on an individual up to any date. The proposed model easily
accommodated highly unbalanced longitudinal data and recurrent events. There were two
levels of structure in the latent class joint model. First, the uncertainty of latent class
membership was specified through a multinomial logistic model. Second, the class-specific
marker trajectory and event process were specified parametrically and semiparametrically,
under the assumption of conditional independence given the latent class membership. They
used a likelihood approach to obtain parameter estimates via the EM algorithm.
2.4 EFFECTIVENESS OF A BIOMARKER AS A SURROGATE
Van der Laan, Hubbard, and Robin discussed locally efficient estimation of a multivari-
ate survival function in longitudinal studies [20]. They considered estimation of the joint
distribution of multivariate survival times T = (T1, . . . , Tk), which were subject to right cen-
soring by a common censoring variables C. Two estimators were proposed: an initial inverse-
probability-of-censoring weighted (IPCW) estimator, and a 1-step estimator. Both estima-
tors incorporated information on available time-independent and time-dependent prognostic
factor (covariate) data. The IPCW estimator was consistent and asymptotically normal
(CAN) under coarsening at random (CAR) and a correct specification of a model for the
hazard of censoring given the past covariate and failure data. The 1-step estimator was a
locally efficient doubly robust estimator. That is, (i) it was CAN under the assumption of
CAR and either (but not necessarily both) correct specification of a model for the hazard
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of censoring given the past or correct specification of a model for the conditional distribu-
tion of T given past failure and covariate information, and (ii) it was efficient when both
these models are correctly specified. The proposed methodology did not required that the
time variables T1, . . . , Tk should be ordered, although their methods covered this important
special case. In particular, their estimators can be used to estimate the gap time distribu-
tions associated with an ordered series of events. The proposed methodology improved over
currently available approached in a number of ways. Specially, when censoring and failure
were dependent because the hazard of censoring depended on both past failure and covariate
history, our one-step estimator is the only estimator with the double robustness property.
When censoring can be assumed to be independent of the failure and covariate process, our
locally efficient one-step estimator did not require smoothing and so will perform well in
moderate size samples even if k is large; further unlike all previous estimators, their esti-
mator exploited the information available in past covariate as well as failure history and so
will be efficient (nearly efficient) even when the components of T were highly dependent,
whenever the specified model for the conditional distribution of T given past failure and
covariate information was correct (nearly correct).
In 2003, Dobson and Henderson commented diagnostic for joint longitudinal and dropout
time modeling [21]. There were three aims to their paper. The first was to propose an ex-
ploratory method designed to assess whether there was any association between responses
and dropout time before any sophisticated and computationally intensive joint modeling
was carried out. They argued that if no systematic differences between subjects who did
or did not drop out can be found in the observed data, then joint modeling is unlikely to
be worthwhile. This idea can be extended to investigate differences between subjects with
different reasons for dropout. Often the reason for dropout from a longitudinal trial was
not stated, but sometimes a reason was given and can be classified as either potentially
informative or otherwise. For instance, being too ill to continue was clearly informative,
whereas leaving the study region may not be. They assumed that there were two categories
of withdrawal, one which might be related to the unobserved response of interest (potentially
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informative dropout), and one which was known or assumed to be independent of the unob-
served response (assumed noninformative dropout). With minor modifications, the methods
can be adapted either to unclassified dropout reasons or to situations where there were more
than two dropout categories of interest. The second aim was to suggest conditional residual
analysis methods for longitudinal data with dropout. They showed that residuals between
observed and expected responses after fitting a joint model can be markedly affected by
knowledge of the dropout time and type, which therefore should properly be taken into ac-
count in an assessment of model adequacy. The final aim was to advocate and illustrate ideas
of case influence for joint modeling. Full case deletion was unrealistic in practice, because
of the computing time required, and some form of approximation was essential. They pre-
sented a variety of informal graphical procedures for diagnostic assessment of joint models for
longitudinal and dropout time data. A random effects approach for Gaussian response and
proportional hazards dropout time was assumed. They considered preliminary assessment
of dropout classification categories based on residuals following a standard longitudinal data
analysis with no allowance for informative dropout. Residual properties conditional upon
dropout information were discussed and case influence was considered. The proposed meth-
ods do not require computationally intensive methods over and above those used to fit the
proposed model.
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3.0 METHODS
3.1 MODEL AND NOTATION
The method of Henderson, Diggle, and Dobson [22] was used to analyze follow-up data
dealing with the longitudinal measurement of a time-varying biomarker. They let Yi(t)
represent the underlying biomarker vector of the ith individual at time t, so that the equation
can be written
Yi(t) = x
′
i1(t)β1 +Wi(t) + ei(t).
where xi1(t) is a p1 × 1 vector of explanatory variables, and Wi(t) and ei(t) are zero-mean
random processes. Since the biomarkers are sampled at discrete time points and assuming
that the Yi are from a normal distribution, a discrete version of the model can be re–written
as
Yij = x
′
ij1β1 +Wij + eij, i = 1, 2, . . . ,m; j = 1, 2, . . . , ni (3.1)
where Wij is the value of a zero-mean Gaussian random effect for the i
th individual at time
j and eij is a zero-mean Gaussian measurement error. The j’s in the discrete version of the
model refer to the last biomarkers observed at or before time t. The errors, eij, are assumed
here to be mutually independent and the within individual correlation in Yij arises through
serial correlation in the random effect, Wij.
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It is assumed that survival time is associated with the longitudinal response through the
effect of the latent process, Wij, but is otherwise conditionally independent. A semipara-
metric proportional hazards model is also assumed and the density function associated with
the hazards model is presented as follows:
f(tij) = S(tij)λ0(tij) exp{x′ij2β2 + γWij} (3.2)
where S(tij) is a predictable survival function, λ0(t) is an unspecified baseline hazard, and
xij2 is a p2 × 1 vector of explanatory variables. The generic notation T, Y and W are used
for survival time, the longitudinal response and the latent process, respectively.
3.2 A SCORE TEST FOR ASSOCIATION BETWEEN LONGITUDINAL
BIOMARKER VALUES AND SURVIVAL TIME FUNCTION
The score test used for testing the parameters of equation (3.2) and is based on separate
analyses of Y and T under the null hypothesis, H0 : γ = 0 and it is assumed that Y is
multivariate Gaussian and T follows a proportional hazards model. Let the combined vector
of unknown parameters be (θ, γ,β2, A0), where θ contains all parameters of the distribution
ofY and let the maximum follow-up time be t. A0(t) denotes the cumulative baseline hazard.
In practice, the usual maximum partial likelihood estimator βˆ2 replaces the unknown β2. A0
(t) is replaced by the non-parametric maximum likelihood estimator (under H0) as follows:
Aˆ0(t) =
∫ t
0
J(u)∑m
i=1 Si(u)e
x′ij2β2
dN(u)
where N(u) =
∑
Ni(u) and J(u) = I(
∑
Si(u) > 0). If W is known, the conditional
likelihood of the survival data can be written as follows:
Lγ = (
∏
j
∏
i
(ex
′
ij2β2+γWij)∆Ni(t)) exp
{
−
∫ τ
0
S(0)γ (t,W,β2)dA0(t)
}
, (3.3)
where S
(0)
γ (t,W,β2) =
∑m
i=1 Si(tij)e
x′ij2β2+γWij
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Let
Uγ(τ) = logLγ =
m∑
i=1
{∫ τ
0
W (tij)dNi(t)−
∫ τ
0
W (tij)S(tij)e
x′ij2β2+γWijdA0(t)
}
(3.4)
and
∂Lγ
∂γ
= Uγ(τ) Lγ
(
because Uγ(τ) =
∂logLγ
∂γ
=
∂Lγ
∂γLγ
)
. (3.5)
The marginal likelihood of the longitudinal measurements is denoted by l1(θ, Y ) and the
overall log likelihood is written as follows:
l = l1(θ, Y ) + logEW |Y [Lγ]
which the derivative with respect to γ is as follows:
∂l
∂γ
=
EW |Y [Uγ(τ)Lγ]
EW |Y [Lγ]
(3.6)
The score statistic is shown as follows:
Uγ(τ) = EW |Y [U0(τ)]
= EW |Y [
m∑
i=1
{∫ τ
0
W (tij)dNi(t)−
∫ τ
0
W (tij)S(tij)e
x′ij2β2dA0(t)
}
]
=
m∑
i=1
EW |Y [W (tij)]dMi(t) (3.7)
where Mi(t) = Ni(t) − Λi(t) = Ni(t) −
∫ tj
0
Si(u)e
x′ij22dA0(u) is the usual counting process
martingale. And U0(τ) is Uγ(τ) under γ = 0. If U (t) is considered a particular value of
a process {U(s) : s > 0} and W is known it is predictable, then the variance of U (s) as
follows:
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V (s) =
m∑
i=1
∫ s
0
EW |Y [W (tij)]2dΛi(t) (3.8)
if the W (tij) between individuals are independent;
or
V (s) =
m∑
i=1
{∫ τ
0
EW |Y [W (tij)]2dΛi(t)−
∫ τ
0
∫ τ
0
CovW |Y (W (tij),W (sij))dMi(t)dMi(s)
}
(3.9)
if the W (tij) between individuals are not independent.
According to the martingale central limit theorem under mild conditions, U(s)/[V (s)](1/2)
is asymptotically N (0, 1) under H0 as m→∞.
3.3 LONGITUDINAL BIOMARKER FOR SURVIVAL
After the longitudinal biomarker is identified and fitted to the data, the fitted model is then
considered to make inference about individuals survival at the future time t = t2 given a
previous time t = t1. If Yi01 is a set of longitudinal measurements on the ith individual over
the interval [0, t1] then the survival function is wrritten as follows:
S(t2 | t1,Yi01) = P (T > t2 | T > t1,Yi01).
Evaluation of the conditional probability of surviving to t2 involves the expectation with
respect to the unobserved latent process. Let Wi01 and Wi02 be the values of W(tij) within
the intervals [0, t1] and [0, t2], respectively. Then S(t2 | t1,Yi01) can be written as
S(t2 | t1,Yi01) =
∫
P (T > t2 | T > t1,W02)f(W02 | T > t1,Yi01)dW02
=
∫
P (T > t2 | T > t1,W02)P (T > t1 |W02)f(W02 | Yi01)dW02
P (T > t1 | Yi01)
=
∫
P (T > t2 |W02)f(Yi01 |W02)f(W02)dW02∫
P (T > t1 |W02)f(Yi01 |W02)f(W02)dW02
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=∫
P (T > t2 |W02)f(Yi01 |W01)f(W02)dW02∫
P (T > t1 |W01)f(Yi01 |W01)f(W01)dW01 . (3.10)
If we ignore any information in Yi01, the conditional probability can be written as:
S(t2 | t1) =
∫
P (T > t2 |W02)f(W02)dW02∫
P (T > t1 |W01)f(W01)dW01 (3.11)
The term f(Yi01 | W02) is a weighting factor which reflects the relevant information in
Yi01. If it is possible to completely determine the true value W
0
02 of W02 from Yi01, then
f(Yi01 |W01)f(W02) and f(Yi01 |W01)f(W01) are zero under W002 6= W02. Now we have
maximum information from Yi01 and S(t2 | t1,Yi01) = S(t2 | t1,W002) under W002 =W02.
3.4 MEASURING BIOMARKER EFFECTIVENESS
Two methods are considered to measure the effectiveness of a biomarker to predict survival
at a future time, t = t2, given the previous time t = t1. One is a fixed point method and the
other is an interval measures method. The key definition is described as follows: S0(tij) is
defined as the value of the observed survivor process for the ith individual at time tj. The
value is one if the individual was known to be alive at tj; the value is zero if the individual
died before tj and the value is undefined if the individual was censored before tj. If the
biomarker is effective, there is the relatively small absolute deviation between S0(tij) and
the corresponding estimates S(t2 | t1,Yi01).
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3.4.1 Fixed point method
In the fixed point method, the unbiased estimator for including the information of Yi01 is as
follows:
MY (τ1, τ2) =
1
r(τ1)
∑
i:ti≥τ1
[
I(ti ≥ τ2)(1− S(τ2 | τ1,Yi01)) + δiI(ti < τ2)
S(τ2 | τ1,Yi01) + (1− δi)I(ti < τ2)
{
(1− S(τ2 | τ1,Yi01))
× S(τ2 | τi,Yi01) + S(τ2 | τ1,Yi01)(1− S(τ2 | τi,Yi01))
}]
, (3.12)
where r(τ1) is the number of individuals at risk at t1 and δi is an indicator of censoring (δi
= 0) or observed failure (δi = 1). And the unbiased estimator without the information of
Yi01 as follows:
M(τ1, τ2) =
1
r(τ1)
∑
i:ti≥τ1
[
I(ti ≥ τ2)(1− S(τ2 | τ1)) + δiI(ti < τ2)
S(τ2 | τ1) + (1− δi)I(ti < τ2)
{
(1− S(τ2 | τ1))
× S(τ2 | τi) + S(τ2 | τ1)(1− S(τ2 | τi))
}]
, (3.13)
A relative measure can be used to interpret the effectiveness of the biomarker by com-
parison of MY (τ1, τ2) and M(τ1, τ2) as follows:
RM(τ1, τ2) = 1−MY (τ1, τ2)/M(τ1, τ2). (3.14)
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3.4.2 Interval measures method
An alternative procedure for measuring the effectiveness of a biomarker is the interval mea-
sures method. The unbiased estimator for including the information of Yi01 for this method
is:
DY (τ1, τ2) =
∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)MY (τ1, ti)∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)
(3.15)
where Gˆ (·) is the Kaplan-Meier estimator of the censoring time distribution, which is used to
compensate for the loss of censored cases. The unbiased estimator without the information
of Yi01 is:
D(τ1, τ2) =
∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)M(τ1, ti)∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)
(3.16)
A relative measure can be used to interpret the effectiveness of the biomarker by com-
parison of MY (τ1, τ2) and M(τ1, τ2) as follows:
RD(τ1, τ2) = 1−DY (τ1, τ2)/D(τ1, τ2). (3.17)
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3.5 THE COMBINATION OF SURVIVAL WITH HETEROGENEOUS
HAZARD ANALYSIS AND LONGITUDINAL DATA ANALYSIS
To formulate our model, we recognize that different individuals in a population can have
vastly different underlying risks of having an event of interest. Consequently, a frailty model
can be used to extend the proportional hazards regression model in survival analysis. Similar
to the formulation of the frailty model provided by Klein and Moeschberger (1997) [23], we
can write the hazard rate at time t in ith patient as
hi(t) = h0(t) exp(ακi + β
txij), i = 1, 2, . . . ,m, j = 1, 2, . . . , ni (3.18)
where h0(t) is an arbitrary baseline hazard rate, xij is the vector of covariates, β is the
vector of regression coefficients, and κ1, . . . , κm are the frailties. It is usually assumed that
the κ’s consist of an independent sample from some distribution with mean 0 and variance
1. If α is zero, then the above equation reduces to Cox’s proportional hazards model. A
more convenient form of model (3.18) can be written as
hi(t) = h0(t)qi exp(β
txij), i = 1, 2, . . . ,m, j = 1, 2, . . . , ni (3.19)
Turning to the longitudinal part of the model, if we let Yi(t) represent the underlying
biomarker vector of the ith individual at time t, then, following Henderson, et al., 2002, we
can write
Yi(t) = x
′
i1(t)β1 +Wi(t) + ei(t). (3.20)
where xi1(t) is a p1 × 1 vector of explanatory variables, and Wi(t) and ei(t) are zero-mean
random processes. Since the biomarkers are sampled at discrete time points and assuming
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that the Yi are from a normal distribution, a discrete version of the model can be re–written
as
Yij = x
′
ij1β1 +Wij + eij, i = 1, 2, . . . ,m, j = 1, 2, . . . , ni , (3.21)
where Wij is the value of a zero-mean Gaussian random effect for the i
th individual at the
jth time point, eij is a zero-mean Gaussian measurement error and ni is the number of
observations for individual i. The j’s in the discrete version of the model refer to the last
biomarkers observed at or before time t. The errors, eij, are assumed here to be mutually
independent and the within individual correlation in Yij arises through serial correlation in
the random effect, Wij.
In a frailty model extension of the proportional hazards regression introduced by Hen-
derson, et al., 2002, the probability density function is
f(t) = S(t)λ0(t)qi exp{x′ij2β2 + γWij} (3.22)
where S(t) is a predictable survival function, λ0(t) is an unspecified baseline hazard, qi is the
unobervable frailty from independent and identically distributed sample of gamma random
variables, and xij2 is a p2×1 vector of explanatory variables. As indicated by equation (3.22),
the connection between the longitudinal process and the failure process is made through the
parameter associated with the latent process, Wij.
For qi, the probabilty density function is
g(q) =
q(1/ν−1) exp(−q/ν)
Γ[1/ν]ν1/ν
. (3.23)
If W is known, the conditional likelihood of the survival data over all times and individ-
uals can be written as follows:
Lγ =
(∏
i
∏
j
(
ex
′
ij2β2+γWij q̂idA0(tij)
)∆N(tij))
exp
{
−
∫ τ
0
S(0)γ (tij,W,β2)dA0(tij)
}
,(3.24)
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where S
(0)
γ (tij,W,β2) =
∑m
i=1 q̂iSi(tij)e
x′ij2β2+γWij and A0(tij) is the cumulative baseline
intensity.
The likelihood of the survival data associated with the frailty conditional on the latent
process, W can be written as follows:
LFULL = Lν × Lγ
=
∏
i
(
q
(1/ν−1)
i exp(−qi/ν)
Γ[1/ν]ν1/ν
∏
j
(
ex
′
ij2β2+γWij q̂idA0(tij)
)∆N(tij))
exp
{
−
∫ τ
0
S(0)γ (tij ,W,β2)dA0(tij)
}
(3.25)
The partial conditional likelihood of the survival data associated with the frailty can then
be written as the sum of the log likehood associated with the frailty distribution plus that
associated with the Cox regresssion model, that is,
`FULL = `ν + `γ(β, γ, A0),
where
`ν = −m
[
(1/ν) ln ν + lnΓ[1/ν]
]
+
m∑
i=1
{
[1/ν − 1] ln qi − qi/ν
}
, (3.26)
and
`γ(β2, γ, A0) =
m∑
i=1
ni∑
j=1
δij[x
′
ij2β2 + γWij + ln dA0(tij)]− qiA0(tij) exp(x′ij2β2 + γWij)(3.27)
where δij is 1 if individual i has an event at the j
th time point and 0, otherwise.
The EM algorithm provides a means of maximizing complex likelihoods. Here we use EM
algorithm described by Klein and Moeschberger (2003) [57]. In the E–step of the algorithm,
the expected value of `FULL is computed, given the current estimates of the parameters and
the observable data. In the M–step of the algorithm, estimates of the parameters which
maximize the expected value of `FULL from the E–step are obtained. The algorithm iterates
between these two steps until convergence.
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To apply the E–step, we’ll assume, similar to Klein and Moeschberger (2003) [24], that
the qi
′s are independent gamma random variables with shape parametersBi = 1/ν+
∑ni
j=1 δij,
and scale parameters, Ci = 1/ν +
∑m
i=1A0(tij) exp(x
′
ij2β2 + γWij). Thus,
E[qi | Data] = Bi
Ci
and E[ln qi] = ψ(Bi)− lnCi, (3.28)
where ψ(·) is the digamma function. Substituting these values in (3.26) and (3.27) completes
the E–step of the algorithm.
For the M–step, E[`γ(β2, γ, A0) | Data] is expressed as
`γ(β2, γ, A0) =
m∑
i=1
ni∑
j=1
δij[(x
′
ij2β2 + γWij) + ln dA0(tij)]−
Bi
Ci
A0(tij) exp(x
′
ij2β2 + γWij)(3.29)
The expression in equation (3.29) is associated with the nuisance parameter dA0().
Now, let t(k) be the k
th smallest event time, and b(k) be the number of events at time t(k),
k = 1, . . . , F . Also, denote the expected value of the frailty and the covariate vector for the
hth individual in the risk set R(t(k)) by q̂h and, xh and Wh, respectively. Then, the partial
likelihood to be maximized in the M–step is
`γ(β2, γ) =
F∑
k=1
S(k) − b(k) ln
[ ∑
h∈R(t(k))
qˆh exp(xh
′β2 + γWh)
] , (3.30)
where S(k) is the sum of the covariates of individuals who had an event at time t(k).
An estimate of A0(tij) from this step is given by
Aˆ0(tij) =
∑
t(k)≤tij
dAk0 (3.31)
where
dAk0 =
b(k)∑
h∈R(t(k)) qˆh exp(xh
′β2 + γWh)
A full implementation of the EM algorithm is as follows (Klein and Moeschberger [2003]):
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Step 0 Provide initial estimates of β2, γ, ν and thus hk0 , k = 1, . . . , F.
Step 1 (E–step) Compute Bi, Ci, i = 1, . . . ,m and qˆh, h = 1, . . . , ni based on the current
values of the parameters.
Step 2 (M–step) Update the estimate of β2, γ (and the dAk0) using the partial likelihood.
Update the estimate of ν based on the likelihood `ν|Data = E[`ν | Data] given by
`ν|Data = −m
[
(1/ν) ln ν + lnΓ(1/ν)
]
+
m∑
i=1
{
[1/ν − 1][ψ(Bi)− lnCi]− Bi
νCi
}
Step 3 Iterate between Steps 1 and 2 until convergence.
Now, let
Uγ(τ) = logLγ =
m∑
i=1
{∫ τ
0
W (tij)dN(tij)−
∫ τ
0
W (tij)qˆiS(tij)e
x′ij2β2+γWijdA0(tij)
}
(3.32)
and
∂Lγ
∂γ
= Uγ(τ) Lγ
(
because Uγ(τ) =
∂logLγ
∂γ
=
∂Lγ
∂γLγ
)
. (3.33)
The resulting score statistic is
Uγ(τ) = EW |Y [U0(τ)]
= EW |Y
[
m∑
i=1
{∫ τ
0
W (tij)dN(tij)−
∫ τ
0
W (tij)qˆiS(tij)e
x′ij2β2dA0(tij)
}]
=
m∑
i=1
EW |Y [W (tij)]dM(tij) , (3.34)
where M(tij) = N(tij) − Λ(tij) = N(tij) −
∫ tij
0
qˆiSi(u)e
x′ij2β2dA0(u) is the usual counting
process martingale (see Fleming and Harrington (1991) [25]) and U0(τ) = Uγ(τ) if γ = 0.
We consider U(t) to be a particular value of a process, {U(s) : s > 0} and W to be
known and predictable so that the variance of U(s) is
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V (s) =
m∑
i=1
∫ s
0
EW |Y [W (tij)]2dΛ(tij), (3.35)
if the W (tij) between individuals are independent; or
V (s) =
m∑
i=1
{∫ τ
0
EW |Y [W (tij)]2dΛ(tij)−
∫ τ
0
∫ τ
0
CovW |Y (W (tij),W (sij))dM(tij)dM(sij)
}
,(3.36)
if the W (tij) between individuals are not independent.
According to the martingale central limit theorem under mild conditions, U(s)/[V (s)](1/2)
is asymptotically N (0, 1) under H0 as m→∞.
3.6 LONGITUDINAL BIOMARKER FOR SURVIVAL WITH
HETEROGENEOUS HAZARD SURVIVAL
In Section 3.3, we showed how a longitudinal biomarker is identified and fitted to data. Next,
the fitted model is used to make inference about individuals’ survival at a future time t =
t2 given an earlier time t = t1. In this section, we extend the model to accommodate frailty
in the survival data. Let Yi01 be longitudinal measurements on the ith individual over the
interval [0, t1]. Then the survival function is as follows:
S(t2 | t1,Yi01, κ) = P (T > t2 | T > t1,Yi01, κ).
This is the same survival function as in section 3.3 but with the addition of a frailty parameter
κ.
Evaluation of the conditional probability of surviving to t2 involves the expectation with
respect to the unobserved latent process. Let Wi01 and Wi02 be the values of W(tij) at
measurement within the intervals [0, t1] and [0, t2], respectively. Then S(t2 | t1,Yi01, κ) can
be written the form as follows:
S(t2 | t1,Yi01, κ) =
∫
P (T > t2 | T > t1,W02, κ)f(W02 | T > t1,Yi01)dW02
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=∫
P (T > t2 | T > t1,W02, κ)P (T > t1 |W02, κ)f(W02 | Yi01)dW02
P (T > t1 | Yi01, κ)
=
∫
P (T > t2 |W02, κ)f(Yi01 |W02)f(W02)dW02∫
P (T > t1 |W02, κ)f(Yi01 |W02)f(W02)dW02
=
∫
P (T > t2 |W02, κ)f(Yi01 |W01)f(W02)dW02∫
P (T > t1 |W01, κ)f(Yi01 |W01)f(W01)dW01 (3.37)
If we ignore any information in Yi01, the conditional probability can be written as:
S(t2 | t1, κ) =
∫
P (T > t2 |W02, κ)f(W02)dW02∫
P (T > t1 |W01, κ)f(W01)dW01 (3.38)
The term f(Yi01 | W01) is a weighting factor which reflects the relevant information in
Yi01. If it is possible to completely determine the true value W
0
02 of W02 from Yi01, then
f(Yi01 | W01)f(W02) and f(Yi01 | W01)f(W01) are zero if W002 6= W02. Now we have
maximum information from Yi01 and S(t2 | t1,Yi01, κ) = S(t2 | t1,W002, κ) if W002 =W02.
3.7 MEASURING BIOMARKER EFFECTIVENESS AT THE SURVIVAL
WITH HETEROGENEOUS HAZARD ANALYSIS
In Section 3.4, two methods were considered to measure the effectiveness of tumor size
to predict survival at time t = t2 given t = t1. One is a fixed point method and the
other was an interval measures method. In this section, both methods will be extended to
again accommodate the multivariate survival data. Again, a frailty model is chosen for the
multivariate data. The key definition is described as follows: S0(tij) is defined as the value
of the observed survivor process for the ith individual at time tj. The value is one if the
individual was known to be alive at tj; the value is zero if the individual died before tj and
the value is undefined if the individual was censored before tj. If the biomarker is effective,
there is a relatively small absolute deviation between S0(tij) and the corresponding estimates
S(t2 | t1,Yi01, κ).
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3.7.1 Fixed point method
In the fixed point method, the unbiased estimator for including the information of Yi01 is as
follows:
MY1(τ1, τ2) =
1
r(τ1)
∑
i:ti≥τ1
[
I(ti ≥ τ2)(1− S(τ2 | τ1,Yi01, κ)) + δiI(ti < τ2)
S(τ2 | τ1,Yi01, κ) + (1− δi)I(ti < τ2)
{
(1− S(τ2 | τ1,Yi01, κ))
× S(τ2 | τi,Yi01, κ) + S(τ2 | τ1,Yi01, κ)(1− S(τ2 | τi,Yi01, κ))
}]
, (3.39)
where r(τ1) is the number of individuals at risk at t1 and δi is an indicator of censoring (δi
= 0) or observed failure (δi = 1). And the unbiased estimator without the information of
Yi01 as follows:
M1(τ1, τ2) =
1
r(τ1)
∑
i:ti≥τ1
[
I(ti ≥ τ2)(1− S(τ2 | τ1, κ)) + δiI(ti < τ2)
S(τ2 | τ1, κ) + (1− δi)I(ti < τ2)
{
(1− S(τ2 | τ1, κ))
× S(τ2 | τi, κ) + S(τ2 | τ1, κ)(1− S(τ2 | τi, κ))
}]
. (3.40)
A relative measure can be used to interpret the effectiveness of the biomarker by com-
parison of MY1(τ1, τ2) and M1(τ1, τ2) as follows:
RM1(τ1, τ2) = 1−MY1(τ1, τ2)/M1(τ1, τ2). (3.41)
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3.7.2 Interval measures method
The alternative procedure for measuring the effectiveness of a biomarker is the interval
measures method. The unbiased estimator for including the information of Yi01 for this
method is:
DY1(τ1, τ2) =
∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)MY1(τ1, ti)∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)
(3.42)
where Gˆ (·) is the Kaplan-Meier estimator of the censoring time distribution, which is
used to compensate for the loss of censored cases. The unbiased estimator without the
information of Yi01 is:
D1(τ1, τ2) =
∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)M1(τ1, ti)∑
i:τ1≤ti≤τ2 δiGˆ(τ1)/Gˆ(ti)
(3.43)
A relative measure can be used to interpret the effectiveness of the biomarker by com-
parison of MY1(τ1, τ2) and M1(τ1, τ2) as follows:
RD1(τ1, τ2) = 1−DY1(τ1, τ2)/D1(τ1, τ2). (3.44)
Equations (3.37) through (3.44) are the same as equations (3.10) through (3.17) except the
latter set of equations includes a frailty parameter, κ.
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4.0 RESULTS
4.1 SIMULATION STUDY
4.1.1 Power of score test for association between longitudinal biomarker values
and survival time function
In order to investigate the empirical properties of the score test for association between
longitudinal biomarker values and the survival time function, we performed a simulation
study which was similar in strategy to that used by Henderson, et al. (2002). However, in
their paper, E[Y ] was a linear function of time and the survival function was exp(−0.1t2),
that is, the failure times were from a Weibull distribution. In our simulation, both E[Y ]
and the survival function are from gamma distributions. We also constructed the survival
function to reflect that every subject has his/her own frailty. We examined the empirical
type I error rates of the score tests, that is, the power under H0 : γ = 0. Other alternative
hypotheses were also explored.
Sample sizes were constructed as follows: total sample size = number of subjects ×
number of observation times or N = n× T . The total number of observations, N , within a
given set of simulations was fixed at a constant number but the number of subjects, n, and
the number of time points, T were varied accordingly. The time points, t, were chosen to be
integer values between 1 and T , inclusively. In each simulation, the frailty parameter varies
across subjects for each simulation. The EM algorithm used for the simulations is provided
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in the coxph function in S-plus 6.2. One thousand (1000) realizations were generated for
each sample size.
In the first set of simulations, we modeled the generated survival data by (correctly)
using frailty parameters to characterize the individuals’ heterogeneous baseline hazards. The
simulation results are shown in Tables 4-1A – 4-1C. Three different latent process types were
specified for assessing the power of score test. The structures for the three different latent
process types are as follows:
(1) :W (t) = U1, U1 ∼ N(0, σ21)
(2) :W (t) = U1 + U2 × t, U1 ∼ N(0, σ21),
U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
(3) :W (t) = U1 + V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ22),
Corr(V (t), V (t+ s)) = exp(−|s|)
We also examined the power of the score test under H0 : γ = 0 while ignoring the exis-
tence of the underlying frailty. Similar situations to those described above were considered
except the frailty was now ignored in the models. Results are shown in Tables 4-2A – 4-2C.
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From the results of Tables 4–1 and 4–2, some empirical properties are as follows:
(1) For latent process types (2) and (3), a higher correlation between longitudinal
biomarker values and survival time function given the large values of σ21 + σ
2
2 results in
higher values for the power of the score test.
(2) For latent process type (1), there are not substantial differences in the power of the
score test for different values of σ21 when the sample sizes are small but when the sample
sizes are large, then for all latent process types, larger values of σ21 result in higher powers
associated with the score test.
(3) For latent process type (2), there are not substantial differences in the power of the
score test for different values of ρ between σ21 and σ
2
2.
By comparing Tables 4–1 and 4–2, one concludes that the power of the score test in
models which correctly specify the existence of the frailty are higher than models that ignore
the existence of the frailty when survival data with heterogeneous hazard structures were
modeled.
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4.1.2 Examination of the measure of biomarker effectiveness in a survival out-
comes with heterogeneous hazard functions
In order to investigate some empirical properties for the measure of biomarker effectiveness
in survival analyses with the presence of heterogeneous hazards among individuals, we con-
ducted more simulations. First, we varied the sample sizes from 25 to 1000 subjects and
varied the number of time points at which the longitudinal biomarkers were measured from
2 to 20. We considered four levels of censoring for the time to event outcome: no censoring,
low censoring (10%), medium censoring (25%) and high censoring (50%).
For this set of simulations, we only considered latent process type (3) as described in
section 4.1.1. Simulation results for the fixed point method (described in section 3.7.1)
are shown in Table 4–3. Simulation results for the interval measure method (described in
section 3.7.2) are shown as Table 4–4. Each entry in Tables 4–3 and 4–4 was based on 1000
realizations of modeling the particular combination of sample size, number of time points
and censoring level.
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4.1.3 Power of the score test for association between longitudinal biomarkers
and survival time when the biomarkers are missing at random
Since the modeling of missing values for longitudinal biomarkers is an important issue, we
also conducted a simulation study to examine its effect on our models. First, we compared
our method with the method of Henderson, Diggle, and Dobson under missing at random
for longitudinal biomarker values, and then we compared our method with the method
of Henderson, Diggle, and Dobson under nonignorable missing for longitudinal biomarker
values. Three different latent process types were specified for assessing the power of score
test. The structures for the three different latent process types are as section 4.1.1 described.
The percentage of missing biomarkers is 50 %. Again, the results of the simulation were based
on 1000 realizations of each scenario.
Simulation results under missing at random for longitudinal biomarker values when ac-
counting for the frailty structure are shown in Tables 4-5A – 4-5C. Results of analogous
simulations but while ignoring the frailty structure are shown in Tables 4-6A – 4-6C.
Comparisons of Tables 4–5 and 4–6 indicate that the power of the score test one specifies
the existence of the frailty structure is higher than that when one ignores the existence of
the frailty .
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4.1.4 Power of the score test for association between longitudinal biomarkers
and survival time when the missingness in the biomarkers is nonignorable
We also considered situations where the missingness in the biomarker values was nonignor-
able. We examined the same situations as for the missing at random cases; namely, 1)
correctly considering the frailty structure and 2) incorrectly ignoring the frailty structure.
Simulation results for situation 1) are shown in Tables 4-7A – 4-7C and for situation 2) are
shown in Tables 4-8A – 4-8C.
Comparisons of Tables 4–7 and 4–8 indicate that the power of the score test is not good
when the missingness of the longitudinal biomarkers is nonignorable regardless of whether
or not the frailty structure is accounted for. However, correctly considering the existence of
the frailty in these models is still better than ignoring its existence.
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4.2 APPLICATION OF EXTENSIONS TO ANALYSIS OF SURVIVAL IN
LIVER CIRRHOSIS PATIENTS
We next consider a dataset from a randomized trial in liver cirrhosis (Andersen, et al. (1993)).
This data was also analyzed by Henderson et al. (2002) and is available on the web site,
http://staff.pubhealth.ku.dk/˜pka/.
4.2.1 Description of the data and the data analysis
There were 488 patients in the trial, 251 patients of whom were assigned into the treatment
(Prednisone) group and 237 patients of whom were assigned into the placebo group. All
patients were followed until death or end of study. The dataset contained several variables:
patient id, treatment status, current prothrombin value, current measurement time, previous
prothrombin value, previous measurement time and a censoring indicator. We focus in
this dissertation on the prothrombin biomarker which is measured repeatedly and on the
treatment variable as they relate to the overall survival in these patients. In the first part of
the analysis, the latent process was considered to be a random effect and was calculated by
using a mixed model approach. Next, the score test for the W (t) model under H0 : γ = 0
was calculated using a Cox frailty model. The results are shown in Table 4–9. Then the
marker effectiveness for prothrombin was determined, the result was shown in Table 4-10.
and Table 4-11. as follows:
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4.2.2 Discussion of our extensions of survival as applied to the liver cirrhosis
dataset
From Table 4–9, it can be seen that whether considering the frailty or not, the score test
for the longitudinal biomarker, prothrombin, under all of three latent process models are
significant. Thus, some would consider this biomarker as a surrogate of survival for patients
who have liver cirrhosis. Comparisons of the results of log likelihood ratio tests from the
three different types of latent models indicate that latent process types (2) and (3) have
larger test values than latent process type (1). Hence, latent process types (2) and (3) are
more suitable than latent type (1) for these data.
From Tables 4–10 and 4–11, one can make conclusions about both the early (Year 0 to
Year 1) and late (Year 3 to Year 4) effectiveness of the prothrombin biomarker as a surrogate
for survival. At early times, the effectiveness of prothrombin is very significant when frailty
is included in the model. In the fixed point method, RM1 for latent process type (1) is 0.243
and for both latent process types (2) and (3) is 0.310. For the interval measure method, RD1
is 0.738 for latent process type (1) and for latent process types (2) and (3) is 0.768. Even
when frailty is not included in the model, the early effectiveness of prothrombin (at times
0 to year 1) is very significant in these liver cirrhosis patients. In fixed point method, RM1
for latent process type (1) is 0.038 and for latent process type (2) and type (3) is 0.294. In
interval measure method, RD1 for latent process type (1) is 0.690 and for latent process type
(2) and type (3) is 0.731.
At late times, the effectiveness of prothrombin was not significant regardless of whether
or not frailty was included in the model. Results also did not change based on whether or
not the fixed point method or the interval measure method was used and was not dependent
on the type of latent process model being used. In all cases, RM1 = 0. Thus, the effectiveness
of the biomarker appears to diminish at late times.
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5.0 DISCUSSION
5.1 DISCUSSION OF OUR EXTENSION
In the Henderson et al paper (2002), they focused only on random effects in the longitudinal
biomarker. They put random effects in the Cox model to determine if longitudinal biomarker
is associated with survival. However, in our method, we deal with random effects from
the longitudinal biomarker and survival. We extended Henderson et al method to deal
with survival with heterogeneous hazard. In our method, we can determine if longitudinal
biomarker is associated with survival while simultaneously considering the existence of frailty
in the survival.
Another aspect of our study was the fact that we estimated the influence of missing data
for power of score test for association between longitudinal biomarker values and survival
time function and biomarker effectiveness. Because the missing data is an important problem
when we analyze the biological and clinical data, we want to know if our method is better
than Henderson et al method under the existence of frailty in the survival.
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5.2 CONCLUSIONS FROM SIMULATION STUDY AND APPLICATION
OF EXTENSIONS OF SURVIVAL IN LIVER CIRRHOSIS PATIENTS
5.2.1 Conclusions from the Simulation Studies
5.2.1.1 Power of score test for association between longitudinal biomarker val-
ues and survival time function For large sample sizes, our model is better for detecting
as a longitudinal biomarker as a predictor for survival data than the method used in the
Henderson et al (2002) paper. However, for small sample sizes, our method also results in
a large overinflation of the α-level as compared to the method using in the Henderson et al
paper. An obvious conclusion is that a larger sample size for the survival data is associated
with a larger power to detect a longitudinal biomarker as a surrogate for survival data than
the small sample size for the survival data.
Also the longitudinal biomarker can be more easily identified as a surrogate for survival
when the random effects from the longitudinal biomarker are either latent process types
(2) or (3). A possible reason is that the latent process types (2) and (3) can show that
the change of random effects is associated with time so they can be adequate to describe
survival situation on an individual level. On the other hand, the latent process type (1) can
show that the change of random effects is not associated with time so it is worse to describe
survival situation in the individual level than the latent process types (2) and (3).
5.2.1.2 Measuring biomarker effectiveness for predicting survival with hetero-
geneous hazard analysis The interval measures method is a modified method for the
fixed point method. The weighting factor for the interval measures method is the numbers
of uncensoring observations between t1 and t2. If the percentage of censoring is high, the
interval measures method is better than the fixed point method if censoring is MCAR.
Given a particular sample size and considering the dependency of the survival data,
an adequate study design to determine if longitudinal biomarkers are surrogates for survival
data to have small numbers of subjects and large numbers of observed time points. Although
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relatively large numbers of subjects and small numbers of observed time points have a relative
large power, assessing biomarker effectiveness is relatively smaller than for small numbers of
subjects and large numbers of observed time points.
5.2.1.3 Power of the score test for association between longitudinal biomarkers
and survival time when the biomarkers are missing at random The power of the
score test under missing at random for the longitudinal biomarker is similar as the one for
the complete data though the power under missing at random for the longitudinal biomarker
is less than the complete data. However, our method appears to be better than the method
of Henderson, Diggle, and Dobson under missing at random for detecting a longitudinal
biomarker when frailty exists in the survival endpoint.
5.2.1.4 Power of the score test for association between longitudinal biomarkers
and survival time when the missingness in the biomarkers is nonignorable The
power of the score test under nonignorable missing shows that the results arsubstantially
worse than the complete data. There is also an even greater overinflation of the α-level.
However, our method appears to be better than the method of Henderson, Diggle, and Dob-
son if frailty exists in the hazard. However, our method cannot distinguish low association
from no association between survival time and the longitudinal biomarkers if the missing-
ness in the longitudinal biomarker is nonignorable. However, it can work on the data under
nonignorable missing for the longitudinal biomarker if there is medium or high association
between survival time and the longitudinal biomarker.
5.3 FURTHUR DIRECTIONS
Our method had several shortfalls. One was the large overinflation of the α-level, that is, the
power under H0, for the score tests when the sample sizes were small. Such an undesirable
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property requires one to consider modifications to our large sample approximations of the
score test to ensure that the α-levels would be closer to nominal values.
Another improvement to the frailty method proposed here would be to combine our
method and methods that deal with both ignorable and nonignorable missing data mecha-
nisms for the longitudinal biomarker. For both biological and clinical data, missing longi-
tudinal values are problematic. Thus, a combined method can be more useful to determine
if an association exists between longitudinal biomarker values even when some are missing
and overall survival which has heterogeneous hazards for different individuals.
Finally, as with most survival methods, informative censoring of the outcome data is
problematic regardless of whether or not the hazard functions are heterogeneous. In this
dissertation, we did not deal with this issue at all. However, it could possibly be fruitful
to model this phenomonom to decrease the bias associated with informative censoring in
time to event outcomes. Such methods could have positive implications for both clinical and
biological applications.
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APPENDIX A
TABLES 1–19
(TABLES 4–1A-4–6B)
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Table 1: Table 4-1A. Power of score test for the W (t) model under H0 : γ = 0 for
latent type (1)†
# of Subjects # of Time Points σ21 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
20 10 1 0.241 0.523 0.754 0.790
20 10 0.8 0.231 0.515 0.732 0.756
20 10 0.2 0.223 0.401 0.428 0.443
25 4 1 0.222 0.570 0.780 0.800
25 4 0.8 0.214 0.554 0.763 0.783
25 4 0.2 0.201 0.506 0.686 0.710
100 20 1 0.205 0.683 0.800 0.830
100 20 0.8 0.193 0.664 0.783 0.820
100 20 0.2 0.181 0.646 0.763 0.810
200 10 1 0.165 0.703 0.810 0.870
200 10 0.8 0.154 0.684 0.794 0.862
200 10 0.2 0.143 0.665 0.773 0.851
500 4 1 0.051 0.726 0.833 0.901
500 4 0.8 0.043 0.715 0.802 0.893
500 4 0.2 0.032 0.703 0.791 0.873
1000 2 1 0.044 0.873 0.901 0.932
1000 2 0.8 0.031 0.864 0.893 0.914
1000 2 0.2 0.021 0.853 0.884 0.903
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 2: Table 4-1B. Power of score test for the W (t) model under H0 : γ = 0 for
latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
20 10 1 1 0.5 1.5 0.227 0.562 0.776 0.856
20 10 1 1 0.05 1.05 0.225 0.543 0.760 0.803
20 10 0.8 0.2 0.5 0.9 0.218 0.531 0.752 0.784
20 10 0.8 0.2 0.05 0.81 0.216 0.514 0.734 0.691
20 10 0.2 0.8 0.5 0.6 0.203 0.453 0.487 0.503
20 10 0.2 0.8 0.05 0.24 0.201 0.433 0.455 0.472
25 4 1 1 0.5 1.5 0.204 0.614 0.801 0.823
25 4 1 1 0.05 1.05 0.202 0.594 0.784 0.806
25 4 0.8 0.2 0.5 0.9 0.194 0.574 0.773 0.788
25 4 0.8 0.2 0.05 0.81 0.192 0.553 0.752 0.769
25 4 0.2 0.8 0.5 0.6 0.183 0.521 0.697 0.718
25 4 0.2 0.8 0.05 0.24 0.181 0.503 0.672 0.695
100 20 1 1 0.5 1.5 0.179 0.704 0.818 0.855
100 20 1 1 0.05 1.05 0.177 0.688 0.794 0.836
100 20 0.8 0.2 0.5 0.9 0.173 0.686 0.793 0.834
100 20 0.8 0.2 0.05 0.81 0.171 0.665 0.772 0.819
100 20 0.2 0.8 0.5 0.6 0.167 0.647 0.771 0.823
100 20 0.2 0.8 0.05 0.24 0.165 0.630 0.751 0.815
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 3: Table 4-1B (continued). Power of score test for the W (t) model under
H0 : γ = 0 for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
200 10 1 1 0.5 1.5 0.151 0.724 0.828 0.910
200 10 1 1 0.05 1.05 0.149 0.708 0.806 0.892
200 10 0.8 0.2 0.5 0.9 0.147 0.706 0.804 0.893
200 10 0.8 0.2 0.05 0.81 0.145 0.685 0.786 0.876
200 10 0.2 0.8 0.5 0.6 0.143 0.683 0.784 0.874
200 10 0.2 0.8 0.05 0.24 0.141 0.667 0.768 0.856
500 4 1 1 0.5 1.5 0.074 0.766 0.873 0.944
500 4 1 1 0.05 1.05 0.045 0.735 0.831 0.906
500 4 0.8 0.2 0.5 0.9 0.064 0.744 0.853 0.925
500 4 0.8 0.2 0.05 0.81 0.054 0.723 0.814 0.893
500 4 0.2 0.8 0.5 0.6 0.051 0.724 0.834 0.903
500 4 0.2 0.8 0.05 0.24 0.034 0.715 0.805 0.871
1000 2 1 1 0.5 1.5 0.053 0.920 0.944 0.964
1000 2 1 1 0.05 1.05 0.041 0.900 0.925 0.934
1000 2 0.8 0.2 0.5 0.9 0.043 0.913 0.936 0.955
1000 2 0.8 0.2 0.05 0.81 0.034 0.896 0.919 0.926
1000 2 0.2 0.8 0.5 0.6 0.035 0.903 0.925 0.944
1000 2 0.2 0.8 0.05 0.24 0.029 0.883 0.892 0.914
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 4: Table 4-1C. Power of score test for the W (t) model under H0 : γ = 0 for
latent type (3)†
# of Subjects # of Time Points σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
20 10 1 1 0.181 0.593 0.791 0.903
20 10 0.8 0.2 0.171 0.565 0.774 0.792
20 10 0.2 0.8 0.162 0.483 0.504 0.525
25 4 1 1 0.173 0.641 0.812 0.842
25 4 0.8 0.2 0.164 0.623 0.781 0.814
25 4 0.2 0.8 0.155 0.568 0.713 0.730
100 20 1 1 0.131 0.727 0.852 0.872
100 20 0.8 0.2 0.123 0.703 0.834 0.866
100 20 0.2 0.8 0.115 0.686 0.816 0.856
200 10 1 1 0.101 0.747 0.852 0.930
200 10 0.8 0.2 0.093 0.723 0.834 0.920
200 10 0.2 0.8 0.086 0.706 0.816 0.911
500 4 1 1 0.051 0.807 0.895 0.975
500 4 0.8 0.2 0.043 0.788 0.876 0.966
500 4 0.2 0.8 0.034 0.765 0.857 0.958
1000 2 1 1 0.042 0.944 0.961 0.990
1000 2 0.8 0.2 0.031 0.935 0.954 0.980
1000 2 0.2 0.8 0.022 0.924 0.943 0.971
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr (V (t), V (t+s)) = exp(−|s|)
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Table 5: Table 4-2A. Power of score test for the W (t) model under H0 : γ = 0 for
latent type (1)†
# of Subjects # of Time Points σ21 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
20 10 1 0.127 0.080 0.121 0.143
20 10 0.8 0.114 0.062 0.093 0.102
20 10 0.2 0.109 0.033 0.062 0.081
25 4 1 0.123 0.086 0.123 0.151
25 4 0.8 0.110 0.065 0.097 0.113
25 4 0.2 0.105 0.037 0.065 0.092
100 20 1 0.104 0.093 0.141 0.183
100 20 0.8 0.098 0.092 0.127 0.162
100 20 0.2 0.092 0.084 0.106 0.141
200 10 1 0.099 0.121 0.161 0.201
200 10 0.8 0.094 0.114 0.144 0.182
200 10 0.2 0.088 0.106 0.122 0.161
500 4 1 0.079 0.132 0.182 0.252
500 4 0.8 0.075 0.123 0.162 0.231
500 4 0.2 0.071 0.111 0.143 0.211
1000 2 1 0.069 0.153 0.213 0.274
1000 2 0.8 0.067 0.142 0.184 0.253
1000 2 0.2 0.063 0.131 0.168 0.231
†Note: W (t) = U1, U1 ∼ N(0, σ21),
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Table 6: Table 4-2B. Power of score test for the W (t) model under H0 : γ = 0 for
latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
20 10 1 1 0.5 1.5 0.103 0.132 0.201 0.254
20 10 1 1 0.05 1.05 0.100 0.113 0.182 0.206
20 10 0.8 0.2 0.5 0.9 0.098 0.104 0.144 0.184
20 10 0.8 0.2 0.05 0.81 0.096 0.082 0.123 0.132
20 10 0.2 0.8 0.5 0.6 0.092 0.061 0.084 0.104
20 10 0.2 0.8 0.05 0.24 0.090 0.051 0.062 0.081
25 4 1 1 0.5 1.5 0.097 0.137 0.204 0.258
25 4 1 1 0.05 1.05 0.095 0.118 0.185 0.208
25 4 0.8 0.2 0.5 0.9 0.093 0.109 0.148 0.187
25 4 0.8 0.2 0.05 0.81 0.091 0.088 0.129 0.136
25 4 0.2 0.8 0.5 0.6 0.088 0.069 0.090 0.107
25 4 0.2 0.8 0.05 0.24 0.086 0.056 0.068 0.089
100 20 1 1 0.5 1.5 0.072 0.145 0.222 0.273
100 20 1 1 0.05 1.05 0.070 0.126 0.182 0.256
100 20 0.8 0.2 0.5 0.9 0.067 0.121 0.204 0.251
100 20 0.8 0.2 0.05 0.81 0.065 0.107 0.186 0.232
100 20 0.2 0.8 0.5 0.6 0.062 0.104 0.182 0.237
100 20 0.2 0.8 0.05 0.24 0.060 0.085 0.163 0.211
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 7: Table 4-2B (continued). Power of score test for the W (t) model under
H0 : γ = 0 for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
200 10 1 1 0.5 1.5 0.070 0.162 0.241 0.294
200 10 1 1 0.05 1.05 0.068 0.143 0.226 0.275
200 10 0.8 0.2 0.5 0.9 0.066 0.142 0.225 0.274
200 10 0.8 0.2 0.05 0.81 0.064 0.123 0.203 0.252
200 10 0.2 0.8 0.5 0.6 0.062 0.121 0.201 0.251
200 10 0.2 0.8 0.05 0.24 0.060 0.103 0.182 0.234
500 4 1 1 0.5 1.5 0.060 0.194 0.275 0.332
500 4 1 1 0.05 1.05 0.058 0.175 0.255 0.304
500 4 0.8 0.2 0.5 0.9 0.057 0.186 0.243 0.303
500 4 0.8 0.2 0.05 0.81 0.055 0.156 0.236 0.286
500 4 0.2 0.8 0.5 0.6 0.054 0.165 0.227 0.284
500 4 0.2 0.8 0.05 0.24 0.052 0.135 0.206 0.263
1000 2 1 1 0.5 1.5 0.056 0.213 0.293 0.351
1000 2 1 1 0.05 1.05 0.054 0.195 0.274 0.324
1000 2 0.8 0.2 0.5 0.9 0.053 0.204 0.264 0.332
1000 2 0.8 0.2 0.05 0.81 0.051 0.176 0.249 0.302
1000 2 0.2 0.8 0.5 0.6 0.050 0.185 0.246 0.303
1000 2 0.2 0.8 0.05 0.24 0.048 0.153 0.221 0.285
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 8: Table 4-2C. Power of score test for the W (t) model under H0 : γ = 0 for
latent type (3)†
# of Subjects # of Time Points σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
20 10 1 1 0.088 0.162 0.226 0.278
20 10 0.8 0.2 0.084 0.136 0.164 0.199
20 10 0.2 0.8 0.080 0.117 0.127 0.136
25 4 1 1 0.079 0.167 0.230 0.282
25 4 0.8 0.2 0.075 0.140 0.169 0.203
25 4 0.2 0.8 0.071 0.131 0.131 0.141
100 20 1 1 0.066 0.193 0.255 0.297
100 20 0.8 0.2 0.063 0.176 0.237 0.279
100 20 0.2 0.8 0.060 0.153 0.216 0.254
200 10 1 1 0.058 0.214 0.276 0.318
200 10 0.8 0.2 0.055 0.197 0.255 0.299
200 10 0.2 0.8 0.052 0.177 0.237 0.276
500 4 1 1 0.052 0.238 0.297 0.354
500 4 0.8 0.2 0.049 0.227 0.278 0.335
500 4 0.2 0.8 0.046 0.209 0.257 0.316
1000 2 1 1 0.048 0.253 0.312 0.383
1000 2 0.8 0.2 0.045 0.242 0.297 0.352
1000 2 0.2 0.8 0.042 0.220 0.275 0.336
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 9: Table 4-3. Measure of marker effectiveness RM1(τ1, τ2) for W (t) model
for latent type (3)† under the different correlation between survival time and
biomarker {Fixed Point Method}
# of # of Time Percentage σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
Subjects Points of Censor
20 10 0 1 1 0.01± 0.047 0.03± 0.049 0.10± 0.050 0.30± 0.052
25 4 0 1 1 0.01± 0.049 0.02± 0.050 0.08± 0.049 0.25± 0.052
100 20 0 1 1 0.10± 0.049 0.15± 0.049 0.30± 0.049 0.65± 0.050
200 10 0 1 1 0.08± 0.050 0.13± 0.050 0.27± 0.049 0.60± 0.051
500 4 0 1 1 0.06± 0.051 0.11± 0.048 0.24± 0.050 0.55± 0.051
1000 2 0 1 1 0.04± 0.049 0.09± 0.048 0.21± 0.049 0.50± 0.051
20 10 10 1 1 0.009± 0.047 0.015± 0.049 0.08± 0.050 0.25± 0.052
25 4 10 1 1 0.009± 0.049 0.01± 0.050 0.06± 0.049 0.20± 0.052
100 20 10 1 1 0.08± 0.049 0.13± 0.049 0.25± 0.049 0.55± 0.050
200 10 10 1 1 0.06± 0.050 0.11± 0.050 0.22± 0.049 0.50± 0.051
500 4 10 1 1 0.04± 0.051 0.09± 0.048 0.19± 0.050 0.45± 0.051
1000 2 10 1 1 0.02± 0.049 0.07± 0.048 0.16± 0.049 0.40± 0.051
20 10 25 1 1 0.007± 0.047 0.01± 0.049 0.06± 0.050 0.20± 0.052
25 4 25 1 1 0.007± 0.049 0.008± 0.050 0.04± 0.049 0.15± 0.052
100 20 25 1 1 0.06± 0.049 0.11± 0.049 0.21± 0.049 0.45± 0.050
200 10 25 1 1 0.04± 0.050 0.09± 0.050 0.19± 0.049 0.40± 0.051
500 4 25 1 1 0.02± 0.051 0.07± 0.048 0.17± 0.050 0.35± 0.051
1000 2 25 1 1 0.01± 0.049 0.05± 0.048 0.15± 0.049 0.30± 0.051
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 10: Table 4-3 (continued). Measure of marker effectiveness RM1(τ1, τ2) for
W (t) model for latent type (3)† under the different correlation between survival
time and biomarker {Fixed Point Method}
# of # of Time Percentage σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
Subjects Points of Censor
20 10 50 1 1 0.005± 0.047 0.008± 0.049 0.04± 0.050 0.15± 0.052
25 4 50 1 1 0.005± 0.049 0.006± 0.050 0.02± 0.049 0.10± 0.052
100 20 50 1 1 0.04± 0.049 0.09± 0.049 0.17± 0.049 0.35± 0.050
200 10 50 1 1 0.02± 0.050 0.07± 0.050 0.15± 0.049 0.30± 0.051
500 4 50 1 1 0.01± 0.051 0.05± 0.048 0.13± 0.050 0.25± 0.051
1000 2 50 1 1 0.008± 0.049 0.03± 0.048 0.11± 0.049 0.20± 0.051
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
56
Table 11: Table 4-4. Measure of marker effectiveness RD1(τ1, τ2) for W (t) model
for latent type (3)† under the different correlation between survival time and
biomarker {Interval Measure Method}
# of # of Time Percentage σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
Subjects Points of Censor
20 10 0 1 1 0.01± 0.047 0.03± 0.049 0.10± 0.050 0.30± 0.052
25 4 0 1 1 0.01± 0.049 0.02± 0.050 0.08± 0.049 0.25± 0.052
100 20 0 1 1 0.10± 0.049 0.15± 0.049 0.30± 0.049 0.65± 0.050
200 10 0 1 1 0.08± 0.050 0.13± 0.050 0.27± 0.049 0.60± 0.051
500 4 0 1 1 0.06± 0.051 0.11± 0.048 0.24± 0.050 0.55± 0.051
1000 2 0 1 1 0.04± 0.049 0.09± 0.048 0.21± 0.049 0.50± 0.051
20 10 10 1 1 0.0095± 0.047 0.02± 0.049 0.09± 0.050 0.28± 0.052
25 4 10 1 1 0.0095± 0.049 0.015± 0.050 0.07± 0.049 0.23± 0.052
100 20 10 1 1 0.09± 0.049 0.14± 0.049 0.27± 0.049 0.60± 0.050
200 10 10 1 1 0.07± 0.050 0.12± 0.050 0.24± 0.049 0.55± 0.051
500 4 10 1 1 0.05± 0.051 0.10± 0.048 0.21± 0.050 0.50± 0.051
1000 2 10 1 1 0.03± 0.049 0.08± 0.048 0.18± 0.049 0.45± 0.051
20 10 25 1 1 0.008± 0.047 0.015± 0.049 0.08± 0.050 0.26± 0.052
25 4 25 1 1 0.008± 0.049 0.01± 0.050 0.06± 0.049 0.21± 0.052
100 20 25 1 1 0.07± 0.049 0.13± 0.049 0.24± 0.049 0.55± 0.050
200 10 25 1 1 0.05± 0.050 0.11± 0.050 0.22± 0.049 0.50± 0.051
500 4 25 1 1 0.03± 0.051 0.09± 0.048 0.20± 0.050 0.45± 0.051
1000 2 25 1 1 0.02± 0.049 0.07± 0.048 0.18± 0.049 0.40± 0.051
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 12: Table 4-4 (continued). Measure of marker effectiveness RD1(τ1, τ2) for
W (t) model for latent type (3)† under the different correlation between survival
time and biomarker {Interval Measure Method}
# of # of Time Percentage σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
Subjects Points of Censor
20 10 50 1 1 0.007± 0.047 0.01± 0.049 0.05± 0.050 0.24± 0.052
25 4 50 1 1 0.007± 0.049 0.008± 0.050 0.05± 0.049 0.19± 0.052
100 20 50 1 1 0.05± 0.049 0.12± 0.049 0.21± 0.049 0.50± 0.050
200 10 50 1 1 0.03± 0.050 0.10± 0.050 0.19± 0.049 0.45± 0.051
500 4 50 1 1 0.02± 0.051 0.08± 0.048 0.17± 0.050 0.40± 0.051
1000 2 50 1 1 0.01± 0.049 0.06± 0.048 0.15± 0.049 0.35± 0.051
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 13: Table 4-5A. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (1)†
# of Subjects # of Time Points σ21 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 0.216 0.674 0.791 0.822
100 20 0.8 0.202 0.653 0.772 0.813
100 20 0.2 0.193 0.635 0.754 0.801
200 10 1 0.174 0.692 0.803 0.864
200 10 0.8 0.162 0.677 0.782 0.851
200 10 0.2 0.154 0.654 0.761 0.843
500 4 1 0.060 0.718 0.824 0.892
500 4 0.8 0.052 0.703 0.793 0.881
500 4 0.2 0.044 0.691 0.782 0.865
1000 2 1 0.052 0.865 0.890 0.924
1000 2 0.8 0.042 0.852 0.884 0.892
1000 2 0.2 0.030 0.845 0.872 0.881
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 14: Table 4-5B. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.5 1.5 0.187 0.695 0.806 0.846
100 20 1 1 0.05 1.05 0.186 0.676 0.782 0.823
100 20 0.8 0.2 0.5 0.9 0.184 0.674 0.781 0.825
100 20 0.8 0.2 0.05 0.81 0.183 0.657 0.764 0.807
100 20 0.2 0.8 0.5 0.6 0.175 0.665 0.762 0.811
100 20 0.2 0.8 0.05 0.24 0.172 0.622 0.743 0.803
200 10 1 1 0.5 1.5 0.163 0.712 0.817 0.901
200 10 1 1 0.05 1.05 0.158 0.695 0.795 0.881
200 10 0.8 0.2 0.5 0.9 0.155 0.694 0.792 0.880
200 10 0.8 0.2 0.05 0.81 0.153 0.673 0.775 0.864
200 10 0.2 0.8 0.5 0.6 0.151 0.671 0.772 0.862
200 10 0.2 0.8 0.05 0.24 0.150 0.655 0.755 0.843
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 15: Table 4-5B (continued). Power of score test for the W (t) model under
H0 : γ = 0 given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
500 4 1 1 0.5 1.5 0.082 0.754 0.865 0.932
500 4 1 1 0.05 1.05 0.053 0.722 0.822 0.894
500 4 0.8 0.2 0.5 0.9 0.072 0.736 0.841 0.913
500 4 0.8 0.2 0.05 0.81 0.062 0.711 0.802 0.881
500 4 0.2 0.8 0.5 0.6 0.060 0.712 0.822 0.892
500 4 0.2 0.8 0.05 0.24 0.042 0.702 0.793 0.863
1000 2 1 1 0.5 1.5 0.061 0.911 0.931 0.952
1000 2 1 1 0.05 1.05 0.050 0.892 0.913 0.923
1000 2 0.8 0.2 0.5 0.9 0.051 0.901 0.922 0.942
1000 2 0.8 0.2 0.05 0.81 0.042 0.887 0.907 0.917
1000 2 0.2 0.8 0.5 0.6 0.046 0.892 0.913 0.932
1000 2 0.2 0.8 0.05 0.24 0.037 0.871 0.881 0.903
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 16: Table 4-5C. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (3)†
# of Subjects # of Time Points σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.140 0.715 0.844 0.864
100 20 0.8 0.2 0.131 0.691 0.822 0.854
100 20 0.2 0.8 0.123 0.673 0.804 0.843
200 10 1 1 0.110 0.735 0.843 0.922
200 10 0.8 0.2 0.102 0.711 0.822 0.911
200 10 0.2 0.8 0.093 0.693 0.804 0.903
500 4 1 1 0.063 0.795 0.883 0.963
500 4 0.8 0.2 0.051 0.775 0.863 0.954
500 4 0.2 0.8 0.042 0.753 0.844 0.946
1000 2 1 1 0.055 0.932 0.952 0.982
1000 2 0.8 0.2 0.040 0.923 0.942 0.973
1000 2 0.2 0.8 0.031 0.912 0.931 0.960
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr (V (t), V (t+s)) = exp(−|s|)
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Table 17: Table 4-6A. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (1)†
# of Subjects # of Time Points σ21 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 0.115 0.081 0.123 0.161
100 20 0.8 0.105 0.080 0.104 0.141
100 20 0.2 0.101 0.072 0.083 0.120
200 10 1 0.107 0.113 0.153 0.193
200 10 0.8 0.103 0.102 0.131 0.170
200 10 0.2 0.096 0.093 0.114 0.153
500 4 1 0.087 0.124 0.170 0.241
500 4 0.8 0.083 0.111 0.151 0.223
500 4 0.2 0.080 0.104 0.134 0.204
1000 2 1 0.077 0.141 0.201 0.262
1000 2 0.8 0.075 0.130 0.172 0.241
1000 2 0.2 0.071 0.123 0.155 0.223
†Note: W (t) = U1, U1 ∼ N(0, σ21),
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Table 18: Table 4-6B. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.5 1.5 0.084 0.135 0.213 0.265
100 20 1 1 0.05 1.05 0.082 0.116 0.170 0.243
100 20 0.8 0.2 0.5 0.9 0.075 0.111 0.192 0.243
100 20 0.8 0.2 0.05 0.81 0.073 0.097 0.173 0.223
100 20 0.2 0.8 0.5 0.6 0.071 0.094 0.171 0.223
100 20 0.2 0.8 0.05 0.24 0.069 0.075 0.152 0.203
200 10 1 1 0.5 1.5 0.080 0.153 0.232 0.282
200 10 1 1 0.05 1.05 0.078 0.131 0.214 0.266
200 10 0.8 0.2 0.5 0.9 0.076 0.130 0.212 0.262
200 10 0.8 0.2 0.05 0.81 0.074 0.111 0.194 0.243
200 10 0.2 0.8 0.5 0.6 0.072 0.110 0.192 0.242
200 10 0.2 0.8 0.05 0.24 0.070 0.092 0.170 0.223
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 19: Table 4-6B (continued). Power of score test for the W (t) model under
H0 : γ = 0 given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
500 4 1 1 0.5 1.5 0.072 0.186 0.267 0.324
500 4 1 1 0.05 1.05 0.066 0.167 0.243 0.293
500 4 0.8 0.2 0.5 0.9 0.064 0.178 0.235 0.292
500 4 0.8 0.2 0.05 0.81 0.063 0.143 0.224 0.273
500 4 0.2 0.8 0.5 0.6 0.062 0.154 0.215 0.272
500 4 0.2 0.8 0.05 0.24 0.060 0.123 0.194 0.251
1000 2 1 1 0.5 1.5 0.063 0.201 0.281 0.342
1000 2 1 1 0.05 1.05 0.062 0.183 0.262 0.312
1000 2 0.8 0.2 0.5 0.9 0.062 0.192 0.257 0.320
1000 2 0.8 0.2 0.05 0.81 0.060 0.164 0.236 0.291
1000 2 0.2 0.8 0.5 0.6 0.059 0.173 0.234 0.291
1000 2 0.2 0.8 0.05 0.24 0.057 0.142 0.210 0.273
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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APPENDIX B
TABLES 20–38
(TABLES 4–6C-4–9(C2))
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Table 20: Table 4-6C. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (3)†
# of Subjects # of Time Points σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.073 0.181 0.243 0.285
100 20 0.8 0.2 0.072 0.164 0.225 0.266
100 20 0.2 0.8 0.071 0.142 0.204 0.242
200 10 1 1 0.066 0.203 0.263 0.305
200 10 0.8 0.2 0.063 0.185 0.243 0.286
200 10 0.2 0.8 0.061 0.164 0.225 0.264
500 4 1 1 0.060 0.226 0.285 0.342
500 4 0.8 0.2 0.057 0.215 0.266 0.323
500 4 0.2 0.8 0.054 0.198 0.245 0.304
1000 2 1 1 0.056 0.242 0.300 0.371
1000 2 0.8 0.2 0.054 0.231 0.285 0.343
1000 2 0.2 0.8 0.050 0.211 0.264 0.324
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 21: Table 4-7A. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (1)†
# of Subjects # of Time Points σ21 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 0.317 0.374 0.396 0.423
100 20 0.8 0.304 0.356 0.371 0.414
100 20 0.2 0.292 0.337 0.352 0.402
200 10 1 0.276 0.395 0.403 0.464
200 10 0.8 0.262 0.373 0.382 0.451
200 10 0.2 0.251 0.353 0.361 0.444
500 4 1 0.163 0.417 0.424 0.493
500 4 0.8 0.152 0.402 0.393 0.480
500 4 0.2 0.145 0.394 0.380 0.464
1000 2 1 0.152 0.564 0.593 0.625
1000 2 0.8 0.145 0.552 0.584 0.591
1000 2 0.2 0.133 0.545 0.575 0.585
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 22: Table 4-7B. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.5 1.5 0.288 0.497 0.607 0.647
100 20 1 1 0.05 1.05 0.285 0.474 0.582 0.624
100 20 0.8 0.2 0.5 0.9 0.284 0.471 0.581 0.622
100 20 0.8 0.2 0.05 0.81 0.280 0.456 0.564 0.607
100 20 0.2 0.8 0.5 0.6 0.278 0.463 0.562 0.611
100 20 0.2 0.8 0.05 0.24 0.272 0.422 0.540 0.603
200 10 1 1 0.5 1.5 0.263 0.514 0.612 0.705
200 10 1 1 0.05 1.05 0.257 0.496 0.594 0.681
200 10 0.8 0.2 0.5 0.9 0.256 0.493 0.596 0.680
200 10 0.8 0.2 0.05 0.81 0.254 0.472 0.573 0.663
200 10 0.2 0.8 0.5 0.6 0.252 0.471 0.572 0.662
200 10 0.2 0.8 0.05 0.24 0.250 0.453 0.556 0.644
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 23: Table 4-7B (continued). Power of score test for the W (t) model under
H0 : γ = 0 given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
500 4 1 1 0.5 1.5 0.182 0.558 0.662 0.731
500 4 1 1 0.05 1.05 0.154 0.526 0.623 0.697
500 4 0.8 0.2 0.5 0.9 0.175 0.533 0.642 0.712
500 4 0.8 0.2 0.05 0.81 0.163 0.512 0.602 0.681
500 4 0.2 0.8 0.5 0.6 0.160 0.510 0.623 0.696
500 4 0.2 0.8 0.05 0.24 0.147 0.502 0.592 0.660
1000 2 1 1 0.5 1.5 0.164 0.712 0.731 0.752
1000 2 1 1 0.05 1.05 0.152 0.693 0.716 0.727
1000 2 0.8 0.2 0.5 0.9 0.151 0.701 0.723 0.743
1000 2 0.8 0.2 0.05 0.81 0.142 0.687 0.705 0.712
1000 2 0.2 0.8 0.5 0.6 0.143 0.692 0.717 0.731
1000 2 0.2 0.8 0.05 0.24 0.137 0.671 0.683 0.702
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 24: Table 4-7C. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (3)†
# of Subjects # of Time Points σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.242 0.515 0.645 0.665
100 20 0.8 0.2 0.232 0.494 0.622 0.653
100 20 0.2 0.8 0.227 0.473 0.603 0.647
200 10 1 1 0.213 0.535 0.644 0.722
200 10 0.8 0.2 0.201 0.514 0.621 0.713
200 10 0.2 0.8 0.197 0.493 0.602 0.700
500 4 1 1 0.164 0.594 0.687 0.962
500 4 0.8 0.2 0.152 0.575 0.663 0.757
500 4 0.2 0.8 0.141 0.552 0.644 0.744
1000 2 1 1 0.154 0.737 0.753 0.982
1000 2 0.8 0.2 0.142 0.723 0.742 0.774
1000 2 0.2 0.8 0.135 0.716 0.735 0.760
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr (V (t), V (t+s)) = exp(−|s|)
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Table 25: Table 4-8A. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (1)†
# of Subjects # of Time Points σ21 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 0.216 0.086 0.125 0.167
100 20 0.8 0.209 0.083 0.103 0.144
100 20 0.2 0.204 0.071 0.089 0.122
200 10 1 0.207 0.114 0.154 0.194
200 10 0.8 0.202 0.102 0.138 0.171
200 10 0.2 0.196 0.097 0.110 0.150
500 4 1 0.187 0.124 0.173 0.244
500 4 0.8 0.183 0.111 0.151 0.226
500 4 0.2 0.180 0.103 0.135 0.203
1000 2 1 0.177 0.146 0.202 0.262
1000 2 0.8 0.174 0.133 0.176 0.244
1000 2 0.2 0.171 0.122 0.154 0.222
†Note: W (t) = U1, U1 ∼ N(0, σ21),
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Table 26: Table 4-8B. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.5 1.5 0.184 0.137 0.155 0.165
100 20 1 1 0.05 1.05 0.182 0.114 0.123 0.144
100 20 0.8 0.2 0.5 0.9 0.173 0.112 0.147 0.140
100 20 0.8 0.2 0.05 0.81 0.172 0.095 0.123 0.125
100 20 0.2 0.8 0.5 0.6 0.171 0.092 0.125 0.121
100 20 0.2 0.8 0.05 0.24 0.169 0.077 0.107 0.105
200 10 1 1 0.5 1.5 0.183 0.152 0.145 0.187
200 10 1 1 0.05 1.05 0.179 0.134 0.152 0.163
200 10 0.8 0.2 0.5 0.9 0.175 0.132 0.153 0.165
200 10 0.8 0.2 0.05 0.81 0.171 0.112 0.144 0.143
200 10 0.2 0.8 0.5 0.6 0.170 0.111 0.143 0.140
200 10 0.2 0.8 0.05 0.24 0.169 0.093 0.131 0.127
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 27: Table 4-8B (continued). Power of score test for the W (t) model under
H0 : γ = 0 given 50 % longitudinal biomarkers missing for latent type (2)†
# of Subjects # of Time Points σ21 σ
2
2 ρ σ
2
1 + σ
2
2ρ γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
500 4 1 1 0.5 1.5 0.171 0.186 0.216 0.227
500 4 1 1 0.05 1.05 0.167 0.167 0.183 0.193
500 4 0.8 0.2 0.5 0.9 0.166 0.173 0.164 0.192
500 4 0.8 0.2 0.05 0.81 0.164 0.144 0.153 0.173
500 4 0.2 0.8 0.5 0.6 0.165 0.157 0.158 0.171
500 4 0.2 0.8 0.05 0.24 0.162 0.122 0.144 0.157
1000 2 1 1 0.5 1.5 0.166 0.205 0.206 0.246
1000 2 1 1 0.05 1.05 0.164 0.187 0.192 0.223
1000 2 0.8 0.2 0.5 0.9 0.163 0.192 0.188 0.220
1000 2 0.8 0.2 0.05 0.81 0.161 0.167 0.167 0.197
1000 2 0.2 0.8 0.5 0.6 0.160 0.173 0.178 0.191
1000 2 0.2 0.8 0.05 0.24 0.158 0.141 0.154 0.170
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 28: Table 4-8C. Power of score test for the W (t) model under H0 : γ = 0
given 50 % longitudinal biomarkers missing for latent type (3)†
# of Subjects # of Time Points σ21 σ
2
2 γ = 0.00 γ = 0.10 γ = 0.25 γ = 0.85
100 20 1 1 0.174 0.187 0.206 0.229
100 20 0.8 0.2 0.173 0.166 0.184 0.206
100 20 0.2 0.8 0.169 0.143 0.162 0.181
200 10 1 1 0.165 0.207 0.228 0.244
200 10 0.8 0.2 0.163 0.187 0.204 0.226
200 10 0.2 0.8 0.160 0.167 0.182 0.204
500 4 1 1 0.158 0.229 0.245 0.261
500 4 0.8 0.2 0.157 0.214 0.234 0.254
500 4 0.2 0.8 0.154 0.195 0.216 0.239
1000 2 1 1 0.151 0.247 0.264 0.287
1000 2 0.8 0.2 0.148 0.230 0.253 0.270
1000 2 0.2 0.8 0.145 0.214 0.237 0.252
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 29: Table 4-9(A1). Liver cirrhosis trial results for the W (t) model for latent
type (1)† under H0 : γ = 0
Est SE
Treatment 0.586 0.7125
Random effect from prothrombin -0.162 0.0182
frailty effect: Chisq = 17633.87, DF = 427
†Note: W (t) = U1, U1 ∼ N(0, σ21)
Table 30: Table 4-9(A2). Score test for the W (t) model for latent type (1)† under
H0 : γ = 0
Chisq DF p
181 29 < 0.001
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 31: Table 4-9(A3). Liver cirrhosis trial results for the W (t) model for latent
type (1)† under H0 : γ = 0 without frailty
Est SE
Treatment 0.0767 0.11742
Random effect from prothrombin -0.0438 0.00346
†Note: W (t) = U1, U1 ∼ N(0, σ21)
Table 32: Table 4-9(A4). Score test for the W (t) model for latent type (1)† under
H0 : γ = 0 without frailty
Chisq DF p
166.49 1 < 0.001
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 33: Table 4-9(B1). Score test for the W (t) for latent type (2)† model under
H0 : γ = 0
Est SE
Treatment -0.319 0.5504
Random effect from prothrombin -0.423 0.0827
frailty effect: Chisq = 14652.33, DF = 436
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
Table 34: Table 4-9(B2). Score test for the W (t) model for latent type (2)† under
H0 : γ = 0
Chisq DF p
272 19 < 0.001
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 35: Table 4-9(B3). Liver cirrhosis trial results for the W (t) model for latent
type (2)† under H0 : γ = 0 without frailty
Est SE
Treatment 0.0832 0.1179
Random effect from prothrombin -0.5350 0.0311
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
Table 36: Table 4-9(B4). Score test for the W (t) model for latent type (2)† under
H0 : γ = 0 without frailty
Chisq DF p
374.49 1 < 0.001
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 37: Table 4-9(C1). Score test for the W (t) model for latent type (3)† under
H0 : γ = 0
Est SE
Treatment -0.319 0.5504
Random effect from prothrombin -0.268 0.0523
frailty effect: Chisq = 14652.18, DF = 436
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
Table 38: Table 4-9(C2). Score test for the W (t) model for latent type (3)† under
H0 : γ = 0
Chisq DF p
272 19 < 0.001
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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APPENDIX C
TABLES 39–52
(TABLES 4–9(C3)-4–11(C2))
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Table 39: Table 4-9(C3). Liver cirrhosis trial results for the W (t) model for latent
type (3)† under H0 : γ = 0 without frailty
Est SE
Treatment 0.0832 0.1179
Random effect from prothrombin -0.3388 0.0197
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
Table 40: Table 4-9(C4). Score test for the W (t) model for latent type (3)† under
H0 : γ = 0 without frailty
Chisq DF p
374.49 1 < 0.001
†Note: W (t) = U1, U1 ∼ N(0, σ21)
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Table 41: Table 4-10(A1). Measure of marker effectiveness for W (t) model
for latent type (1)† under the different correlation between survival time and
biomarker {Fixed Point Method}
Time MY1 M1 RM1
[0, 1) 0.559 0.738 0.243
[3, 4) 0.817 0.817 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
Table 42: Table 4-10(A2). Measure of marker effectiveness for W (t) model
for latent type (1)† under the different correlation between survival time and
biomarker without frailty{Fixed Point Method}
Time MY1 M1 RM1
[0, 1) 0.242 0.252 0.038
[3, 4) 0.583 0.583 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 43: Table 4-10(B1). Measure of marker effectiveness for W (t) model
for latent type (2)† under the different correlation between survival time and
biomarker {Fixed Point Method}
Time MY1 M1 RM1
[0, 1) 0.510 0.738 0.310
[3, 4) 0.817 0.817 0.000
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
Table 44: Table 4-10(B2). Measure of marker effectiveness for W (t) model
for latent type (2)† under the different correlation between survival time and
biomarker {Fixed Point Method}
Time MY1 M1 RM1
[0, 1) 0.203 0.252 0.294
[3, 4) 0.583 0.583 0.000
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 45: Table 4-10(C1). Measure of marker effectiveness for W (t) model
for latent type (3)† under the different correlation between survival time and
biomarker {Fixed Point Method}
Time MY1 M1 RM1
[0, 1) 0.510 0.738 0.310
[3, 4) 0.817 0.817 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
Table 46: Table 4-10(C2). Measure of marker effectiveness for W (t) model
for latent type (3)† under the different correlation between survival time and
biomarker {Fixed Point Method}
Time MY1 M1 RM1
[0, 1) 0.203 0.252 0.294
[3, 4) 0.583 0.583 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 47: Table 4-11(A1). Measure of marker effectiveness for W (t) model
for latent type (1)† under the different correlation between survival time and
biomarker {Interval Measure Method}
Time DY1 D1 RD1
[0, 1) 0.134 0.511 0.738
[3, 4) 0.817 0.817 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
Table 48: Table 4-11(A2). Measure of marker effectiveness for W (t) model
for latent type (1)† under the different correlation between survival time and
biomarker {Interval Measure Method}
Time DY1 D1 RD1
[0, 1) 0.016 0.052 0.690
[3, 4) 0.583 0.583 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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Table 49: Table 4-11(B1). Measure of marker effectiveness for W (t) model
for latent type (2)† under the different correlation between survival time and
biomarker {Interval Measure Method}
Time DY1 D1 RD1
[0, 1) 0.119 0.511 0.768
[3, 4) 0.817 0.817 0.000
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
Table 50: Table 4-11(B2). Measure of marker effectiveness for W (t) model
for latent type (2)† under the different correlation between survival time and
biomarker {Interval Measure Method}
Time DY1 D1 RD1
[0, 1) 0.014 0.052 0.731
[3, 4) 0.583 0.583 0.000
†Note: W (t) = U1 + U2 × t, U1 ∼ N(0, σ21), U2 ∼ N(0, σ22), Corr(U1, U2) = ρ
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Table 51: Table 4-11(C1). Measure of marker effectiveness for W (t) model
for latent type (3)† under the different correlation between survival time and
biomarker {Interval Measure Method}
Time DY1 D1 RD1
[0, 1) 0.119 0.511 0.768
[3, 4) 0.817 0.817 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
Table 52: Table 4-11(C2). Measure of marker effectiveness for W (t) model
for latent type (3)† under the different correlation between survival time and
biomarker {Interval Measure Method}
Time DY1 D1 RD1
[0, 1) 0.014 0.052 0.731
[3, 4) 0.583 0.583 0.000
†Note: W (t) = U1+V (t), U1 ∼ N(0, σ21), V (t) ∼ N(0, σ21), Corr(V (t), V (t+s)) = exp(−|s|)
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